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Tutti abbiamo una ferita segreta per riscattare la quale combattiamo. 
(I. Calvino, Il sentiero dei nidi di ragno, 1947) 
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List of abbreviations 
 
6-OHDA   6-hydroxydopamine 
ANOVA   analysis of variance 
BG    basal ganglia 
BNTX   7-benzyldenenaltrexone 
CCG    Center of Chemical Genomics, University of Michigan 
CNS    central nervous system 
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DA    dopamine 
DAMGO   [D-Ala2,N-MePhe4,Gly-ol]-enkephalin 
DELT    [D-Ala2, D-Glu4]-deltorphin 
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DPDPE   [D-Pen2,D-Pen5]-enkephalin 
DYN    dynorphin 
EM    endomorphin 
ENK    enkephalin 
GABA   γ-amino butyric acid 
GAPs    GTPase-accelerating proteins 
GDP    guanosine-5’ diphosphate 
GEF    guanine-nucleotide-exchange factor 
GF-4  1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-
tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one 
GIRK    G-protein inwardly rectifying potassium channel 
GP    globus pallidus 
GPCR    G-protein coupled receptor 
GRK    G-protein coupled receptor kinase 
GTP    guanosine-5’ triphosphate 
GTPase   guanosine triphosphatase 
GP    globus pallidus 
HEK    human embryonic kidney cells 
i.c.v.    intracerebroventricular 
i.p.    intraperitoneal 
J-113397  1-[(3R,4R)-1-cyclooctylmethyl1-3-hydroxymethyl1-4-piperidyl]-3-       
ethyl-1,3-dihydro-2H-benzimidazol-2-one 
5 
KOP    κ-opioid peptide 
L-DOPA   3,4-dihydroxyphenylalanine 
MOP    μ-opioid peptide 
MPTP    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
N/OFQ    nociceptin/orphanin FQ 
NAcc    nucleus accumbens 
NOP    nociceptin/orphanin FQ peptide 
NTB    naltriben 
NTI    niltrindole 
PDYN   pro-dynorphin 
PENK    pro-enkephalin 
PD    Parkinson’s disease 
PDZ    PSD95/Dlg/Z0-1 domain 
POMC   pro-opiomelanocortin 
PPIs    protein-protein interactions 
PPIIs    protein-protein interactions inhibitors 
PTX    pertussis toxin 
RGS    regulator of G-protein 
RGS4    regulator of G-protein 4 
RM    repeated measures 
SNc    substantia nigra compacta 
SNr    substantia nigra reticulata 
SNC-80  (+)-4-[(αR)-α-(2S,5R)-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxy-    
benzyl]-N,N-diethylbenzamide 
TM    trans-membrane 
Trap-101  1-[1-(Cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-    
pyridinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one hydrochloride 
UFP-101   [Nphe1,Arg14,Lys15]Nociceptin-NH2 
UFP-512   H-Dmt-Tic-NH-CH(CH2-COOH)-Bid 
VTA    ventral tegmental area 
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Introduction 
 
The opioid system 
The term “opioid” was coined by Acheson referring to all compounds with a morphine-like 
action and distinct chemical structures ranging widely from alkaloids to peptides. The use of 
opioid analgesics has a long history, dating back over five millennia. Despite the flow of time 
and the energies of scientists around the world, however, the functions of opioid receptors in 
the brain is not well understood until these days. 
The opioid receptor system plays a central role in pain control and is a key regulator of 
hedonic homeostasis, mood and wellbeing. It is now understood that morphine and other 
opioid drugs are not only involved in setting pain (nociceptive) threshold and in controlling 
nociceptive processing but also participate in modulation of gastrointestinal, endocrine and 
autonomic function, and play a possible role in cognition. In the past two decades, the 
refinement of pharmacological tools and the generation of genetic models have helped clarify 
the specific role of each opioid receptor subtypes in many aspects of opioid-related physio-
pathology. 
The existence of receptors for opiate drugs was proposed by Beckett and Casy in 1954 based 
on their studies on structure-activity relationships for antinociceptive activity (e.g. the ability 
to relieve pain) in a series of synthetic opiates. They proposed a unique opioid receptor that 
followed the lock and key mechanism to interact with opioids
1
, but there were several 
anomalies that did not fit the postulated structurally rigid receptor, which allowed the binding 
of diverse molecules with a morphine-like structure. As early as 1965, based on structure-
activity analysis studies, Portoghese proposed the existence of more than one opioid receptor 
type or the possibility of multiple modes of interaction between ligands and opioid receptors
2
. 
Evidence for the existence of multiple opioid receptor subtypes arose from work identifying 
the different anatomical location and pharmacological profiles of compounds that were 
eventually used to name them, i.e. morphine (mu), ketocyclazocine (kappa)
3
 and vas deferens 
(delta)
4
. Recently, a fourth opioid-like receptor has been included in the opioid receptor 
family and has been termed opioid-like receptor 1 (ORL-1)
5
. This receptor was originally 
placed within the opioid family due to sequence and functional homologies, it produces 
downstream effects that are similar to those of the other three opioid receptors, but it does not 
interact with high affinity with classical opioid ligands. Receptor nomenclature has varied 
several times over the years and the most recent classification proposed by the International 
Union of Pharmacology (IUPHAR) is mu-opioid peptide (MOP) receptor, kappa-opioid 
7 
peptide (KOP) receptor, delta-opioid peptide (DOP) receptor and nociceptin/orphanin FQ 
(N/OFQ) peptide (NOP) receptor. 
Opioid receptors are the endogenous targets of neuropeptides derived from three distinct 
protein precursors encoded by pro-opiomelanocortin (POMC), pro-enkephalin (PENK), and 
pro-dynorphin (PDYN) genes
6
. POMC encodes the peptide β-endorphin, which has agonist 
activity at both MOP and DOP receptors. Differently from the other endogenous opioids, the 
biosynthetic pathway of endomorphin-1 (EM-1) and endomorphin-2 (EM-2), which are both 
selective for the MOP receptor, is still unclear. The endogenous DOP receptor peptides are 
met-enkephalin (met-ENK) and leu-enkephalin (leu-ENK), cleaved from PENK. PDYN gives 
rise to the KOP receptor agonists dynorphin A (DYN-A) and dynorphin B (DYN-B)
7,8
, whilst 
N/OFQ is from the polypeptide precursor pro-N/OFQ (Tab. 1). 
 
Propeptide Peptide(s) Preferential receptor 
POMC β-endorphin MOP/DOP* 
Not known Endomorphin-1 
Endomorphin-2 
 
MOP 
PENK Met-enkephalin 
Leu-enkephalin 
 
DOP 
PDYN Dynorphin A 
Dynorphin B 
 
KOP 
Pro-orphanin FQ Orphanin FQ NOP 
Table 1. Brain opioid peptides, their precursor molecules and preferential binding sites. * β-endorphin binds 
with rather similar affinity to both MOP and DOP receptor
9
. 
 
Each type of opioid receptors is differentially localized in the central nervous system (CNS), 
and the striatum has the highest levels of endogenous opioid peptides and receptors
8,10
. 
Opioid receptors are G-protein coupled receptors (GPCR), and share a similar seven 
transmembrane structure, the highest homology occurring in the trans-membrane (TM) 
domains, intracellular loops and C-terminus
6
. However, it is surprising that all the cloning 
studies pointed just to three different gene products when the literature at the time suggested 
the existence of three MOP (µ1, µ2, µ3), two DOP (δ1 and δ2), and three KOP (κ1, κ2, κ3) 
receptor subtypes, based on distinct pharmacological properties. 
Opioids have predominantly direct inhibitory effects on cells in the CNS, which are mediated 
through the activation of pertussis toxin (PTX) sensitive Gi/0-proteins. This leads to inhibition 
of adenylyl cyclase and voltage-activated Ca
2+
 channels, and activation of inwardly rectifying 
8 
K
+
 channels, leading to reduced excitability and inhibition of neurotransmitter release
11
 (Fig. 
1). Despite these inhibitory effects at the cellular level, opioids have excitatory actions in 
multiple regions of the nervous system in vivo. Excitation by opioids is generally attributed to 
inhibition of inhibitory pathways (disinhibition). However, recent studies indicate that opioids 
can directly excite individual cells. These effects may occur when opioid receptors interact 
with other GPCR such as receptor tyrosine kinases
12
. 
 
 
Figure 1. The best characterized pathway of effector activation by opioids. Three primary classes of effectors 
include the inhibition of adenyl cyclase, inhibition of vescicular release, and interactions with a number of ion 
channels. These effectors are affected by the GTP-bound form of α-subunit as well as by free β/γ-subunits of 
pertussis toxin-sensitive G protein. GIRK, G protein inwardly rectifying potassium channel. 
 
MOP receptors 
The MOP receptor was the last of the classical opioid receptors to be cloned
13
. It is located 
throughout the central nervous system in areas involved in sensory and motor function 
including regions involved in the integration and perception of the senses. The highest density 
of MOP receptors is found in the CPu (of the BG). High density is also found in the 
neocortex, thalamus, nucleus accumbens (NAcc), hippocampus and amygdala
14
. MOP 
receptors are located pre-synaptically on primary afferent neurons within the dorsal horn of 
the spinal cord where they inhibit glutamate release and hence transmission of nociceptive 
stimuli
15
. MOP receptors mediate positive reinforcement following direct (morphine) or 
indirect (alcohol, cannabinoids, nicotine) stimulants, and the understanding of MOP receptor 
function is central to the development of therapies for addiction. 
The endogenous ligands for the MOP receptor are EM-1 and EM-2
16
, and the finding that the 
analgesic and addictive properties of morphine are abolished in mice lacking the MOP 
receptor has unambiguously demonstrated that MOP receptors mediate both the therapeutic 
and the adverse activities of this compound
17
.  
9 
Based on binding and pharmacological studies, the existence of various subtypes of the MOP 
receptor has been postulated, but only one receptor has been cloned
18,19
. At least 10 variants 
have been identified, some of which express truncated forms of the receptor, or variations in 
the intracellular tip of the C-terminus of the receptor
20,21
. These have been defined using 
knockout mice, antisense mapping studies, and studies showing subtype differences in agonist 
affinity and analgesia. 
MOP receptor agonists are known to stimulate locomotion when given at low doses, and 
sedation at higher ones
22
. As a matter of facts, selective MOP receptor stimulation in the 
substantia nigra reticulata (SNr) facilitates spontaneous locomotion and turning behavior in 
rats
23
. The effect on locomotion can be correlated with the MOP receptor-dependent 
dopamine (DA) release in striatal areas
24
 and the control of GABAergic nigro-thalamic output 
neurons
25
.  
Whilst the analgesic effect of opioids is elicited by central activation of opioid receptors, a 
number of the common side-effects, including reduced gastrointestinal motility, leading to 
constipation, urinary retention and pruritus, are regulated by activation of peripherally located 
opioid receptors. Major side-effects associated with MOP agonists include respiratory 
depression through a reduction in the sensitivity of central and peripheral chemoreceptors to 
hypercapnia. MOP opioids also have effects on the cardiovascular system, thermoregulation, 
hormone secretion and immune function. 
Studies using MOP receptor knockout mice have defined the role that the MOP receptor plays 
tonically and when stimulated by exogenously applied ligands. MOP receptor knockout mice 
show increased sensitivity to thermal pain, implicating the receptor in this mode of 
nociception. However, no change in threshold of mechanic pain was seen
26
. None of the 
predicted effects or side-effects of morphine were seen in mice lacking the MOP receptor, 
suggesting that both the wanted and unwanted effects of morphine are attributable to action at 
the MOP receptor
27
. 
 
DOP receptors 
The DOP receptor was the first to be cloned
28
 and is less widely distributed compared to the 
other opioid receptors. Highest densities are found in the olfactory bulb, cerebral cortex, 
NAcc and CPu. DOP receptors are located mostly pre-synaptically on primary afferents 
where they inhibit the release of neurotransmitters.  
The DOP receptor mediates the antinociceptive/analgesic actions of some opioids through 
both spinal and supraspinal sites. Indeed, DOP receptor agonists induced clear antinociceptive 
responses in several acute
29
 and chronic
30
 models of pain in rodents, although some of these 
10 
effects might be partially due to a cross-reactivity with MOP receptor
31
.  
The DOP receptor has high affinity for leu/met-ENKs which are its endogenous ligands. 
Although only one DOP gene has been cloned thus far, recent evidence regarding the direct 
antinociceptive effects of DOP receptor agonists has suggested that at least two DOP subtypes 
are expressed: the putative δ1 subtype (DOP1) and the putative δ2 subtype (DOP2). The 
putative DOP1 subtype is preferentially activated by [D-Pen2, D-Pen5] enkephalin (DPDPE) 
and antagonized by 7-benzylidenenaltrexone (BNTX), while the putative DOP2 subtype is 
preferentially activated by [D-Ala2, D-Glu4] deltorphin (DELT) and blocked by naltriben 
(NTB)
32,33
. This was also confirmed by the lack of cross-tolerance between DPDPE and 
DELT
34
. Several studies on the antinociceptive actions of combined DOP receptor subtype 
agonists and antagonists support these findings
35-38
. On the other hand, some of the 
pharmacological effects of DOP agonists may appear through partial activation of other 
opioid receptors
39
 or heterodimer forms of the DOP receptor
40,41
. 
The generation of mice lacking either MOP or DOP receptors has allowed to revisit the 
selectivity of prototypical DOP receptor agonists under in vivo experimental conditions. In 
DOP knockout animals, the analgesia induced by the agonists DPDPE and deltorphin was 
either abolished, reduced, or maintained, depending on the nociceptive assay and route of 
administration
42
; the observation of residual activity of DOP receptor agonists in DOP 
receptor-deficient animals strongly supports the cross-reactivity of DOP at MOP receptors in 
vivo
43
. MOP and DOP receptors are usually considered to act similarly in most opioid-
controlled behaviors. In fact, both MOP receptor agonists and DOP receptor agonists have 
been shown to reduce gastrointestinal tract motility and cause respiratory depression
6
. It was, 
therefore, surprisingly the finding of opposing phenotypes in DOP and MOP deficient mice in 
several behavioral models, when the two mutants strains were studied in parallel (e.g., DOP 
receptor knockout mice displayed anxiogenic and depressive-like responses 
44
, while MOP 
receptor mutants showed opposite responses).  
A great deal of data suggests a significant but complex role of DOP receptor in the regulation 
of motor activity; the DOP receptor is strongly expressed in the striatum, and ENKs act as co-
transmitters in striatal GABAergic neurons projecting to globus pallidus (GP)
45,46
. Here, they 
inhibit GABA release from striato-pallidal terminals
47
, thereby opposing the inhibitory post-
synaptic influence produced by striato-pallidal neurons
48
. This facet of DOP receptor function 
is of potential interest in diseases involving impaired motor control such as Parkinson’s 
disease (PD). Indeed, striatopallidal neurons become pathogenically overactive following DA 
depletion, leading to overinhibition of pallido-subthalamic GABAergic and disinhibition of 
subthalamo-nigral glutamatergic projections
49
. Consequently, PENK-A expression in 
11 
striatopallidal neurons rises
50,51
, possibly to attenuate exaggerated GABA release and 
compensate for motor deficit
47
. Consistently, the DOP agonist SNC-80 reversed akinesia and 
showed locomotor-stimulating properties in reserpinized or haloperidol-treated rats as well as 
MPTP-treated marmosets
40,30,47,52-55
. In 2009, Mabrouk and collegues
56
 showed that the DOP 
receptor agonist UFP-512 increased locomotor coordination in a hemiparkinsonian rat model 
at low doses and had opposite effects at higher ones. Also, the DOP receptor antagonist NTI 
diminished abnormal movements classically described in the 6-OHDA model
57
. More 
recently, the most recently developed DOP receptor agonists do not show locomotor-
activating properties
54,55,58-60
. Therefore, agonist-biased activity for different DOP receptor 
agonists may occur.  
 
KOP receptors 
The KOP receptor was the second of the opioid receptor family to be cloned
61
. Its endogenous 
ligand is DYN A and the prototypical exogenous agonist at KOP receptor is the non-peptide 
benzomorphan ketocyclazocine, the actions of which have been shown to be distinct from 
those elicited by stimulation of the MOP receptor (e.g. sedation without marked effects on 
heart rate). The side-effects elicited by KOP receptor agonists have, to date, limited their 
clinical use. However, it has been shown that KOP agonists (e.g. enadoline) may have 
neuroprotective actions via their ability to inhibit post-ischemic glutamate release
62
. 
Enadoline has also been reported to increase locomotion in monoamine-depleted rats
63
; the 
same group demonstrated a synergistic effect between enadoline and L-DOPA, suggesting 
that KOP receptor agonists might be used as adjuncts to L-DOPA therapy in PD. However, 
clinical studies using the KOP receptor agonist spiradoline (U-62066) failed to prove its 
efficacy alone or in combination with L-DOPA in the treatment of PD
64
. Indeed, KOP 
receptors are localized in the rat SNr but are not detectable in SNc
65
, placing this peptide 
receptor system in a strategic position to modulate the output of BG and motor function. 
Nonetheless, KOP receptor agonists have been shown to produce contrasting effects 
compared to MOP and DOP receptor agonists in a number of behavioral paradigms. For 
instance, KOP receptor stimulation reduced locomotor activity in naïve mice while DOP
66
 
and MOP
22
 stimulation enhanced it. Additionally, KOP receptor agonists have been shown to 
produce dysphoria in contrast to the euphoria brought about by MOP receptor agonists
67
. 
The advantage of KOP receptor agonists over MOP or DOP receptor agonists is that they do 
not cause respiratory depression. It should also be mentioned that KOP agonists also exert an 
anti-opioid action, attenuating analgesia elicited by endogenously released or exogenously 
administered MOP agonists. 
12 
NOP receptors 
In 1995, the endogenous agonist for the NOP receptor was isolated by two independent 
groups. This neuropeptide was termed nociceptin by Meunier et al.
68
, and orphanin FQ by 
Reinscheid et al.
5
. It is now commonly referred to as nociceptin/orphanin FQ (N/OFQ). There 
is a significant similarity between the amino acid sequences of N/OFQ and those of classical 
opioid peptides; this resemblance is particularly stricking in the case of DYN-A. Also, at the 
cellular level, N/OFQ produces actions similar to those of classical opioids, resulting in 
reduced neuronal excitability and inhibition of transmitter release. Despite these analogies 
with the opioid system, N/OFQ does not bind with high affinity to the classic opioid 
receptors
5
. Accordingly, the N/OFQ system has evolved into a distinct and independent 
system
69-71
. 
Initial studies concentrated on the role N/OFQ in pain. However, exogenous N/OFQ 
administration has also been shown to modulate locomotion, stress and anxiety, feeding
72,73
, 
learning and memory
74-76
, reward/addiction, and neuroendocrine response to stress
77,78
. 
Under laboratory conditions, N/OFQ has been shown to have a pronociceptive, anti-analgesic 
effect when applied supraspinally, whilst causing analgesia when applied spinally. N/OFQ 
anti-opioid action is the most likely cause for the supraspinal pronociceptive effect. N/OFQ 
might inhibit either endogenous opioid tone or stress-induced analgesia produced during 
testing procedures in laboratory animals. It is believed that endogenous levels of N/OFQ may 
act to set threshold to pain, as NOP receptor antagonists have been shown to produce a long 
lasting analgesia of similar extent to that of morphine. Therefore, NOP receptor antagonists 
have been proposed as novel analgesics or adjuvants to classical therapies, to reduce the 
amount of opioid analgesics and the side-effects correlated.  
The generation of useful research tools, particularly transgenic animals and selective receptor 
ligands (especially antagonists) facilitated the understanding of the complex biological roles 
played by N/OFQ. Knockout mice for the N/OFQ precursor (ppN/OFQ
-/-
)
79
 or the NOP 
receptor (NOP
-/-
)
80
 are available; more recently NOP
-/-
 rats were also generated
81
. 
NOP receptor knockout mice show a partial loss of tolerance to morphine, which is consistent 
with the up-regulation of N/OFQ production in chronic morphine tolerant mice
82
. Studies in 
knockout mice confirmed that morphine tolerance to analgesia, but not acute response to 
morphine, was markedly attenuated. This action has also been confirmed through the actions 
of potent selective NOP antagonists, which also attenuate morphine tolerance. These findings 
suggest the N/OFQ–NOP system contributes to neuronal plasticity involved in the 
development of tolerance seen with chronic morphine exposure. 
 
13 
Opioids and dopamine system 
Previous reports have shown that the involvement of opioid receptors in behavioral or 
rewarding effects depends on the central DA system, although contradictory reports also exist. 
Indeed, there is a body of evidence indicating that the rewarding or motivational effects of 
exogenously administered opioids are purely secondary to activation of the mesolimbic DA 
system
83-86
, although the involvement of D1 versus D2 receptors is controversial
86,87
. On the 
other hand, the absolute requirement of an intact DA system for the opioid action has been 
challenged, and DA-independent mechanism of opiate reward has been proposed
88-93
. 
Major depressive disorder was shown to be associated with a reduction in response to 
rewarding stimuli in the dopaminergic mesolimbic pathway in a recent neuroimaging study
94
. 
This neuronal network is modulated by opioids, typically by MOP and DOP receptors, at the 
level of DA neurons and afferent structures. Therefore, a deficit in endogenous opioids, 
mainly ENKs, in the NAcc and ventral tegmental area (VTA), may lead to a decrease in the 
neurobiological control of mood states and reward. 
A plethora of studies supports the cross-talk between the opioid and the DA systems; for 
example, the conditioned place preference induced by morphine or heroin is attenuated by 
either pretreatment with DA receptor antagonist
85,95
 or 6-hydroxydopamine (6-OHDA) lesion 
of the NAcc, the terminal area of the mesolimbic DA projections
85
. Moreover, chronic 
administration of the DA D1 receptor antagonist SCH23390 during conditioning sessions also 
attenuates both the morphine-induced place preference
96-98
 and the KOP receptor agonist 
induced place aversion
96,97
.  
DOP and MOP receptors are highly concentrated in the striosomes, one of the functional 
subdivisions of the mosaic structure of the mammalian striatum
99
. Striosome compartment 
has been implicated in motor and behavioral brain functions
100
 and their disorders
101-103
. 
Striosomal opioid signaling has emerged as a potent regulator of striatal activity
104
, whereas 
its functional significance in the pathophysiology of movement disorders remains to be 
elucidated.  
An enhancement of opioid transmission is thought to play a compensatory role in altered 
functions of the BG under the conditions of striatal DA depletion in PD
8,105
. However the 
precise mechanism by which the increased opioid signaling modulates the BG activity is still 
under debate. One of the most recognized models of functional organization of the BG 
indicates a key role for balance in the activity of the two major striatal output pathways, i.e., 
the direct and indirect pathways
106
. DA depletion is known to enhance opioid transmission in 
the striatum
107
; strikingly, this is found to occur in medium spiny neurons (MSNs) that form 
the indirect pathway. The level of expression of ENKs and PPE-A mRNA is increased in 
14 
striato-pallidal MSNs
108-110
, whereas that of DYN and PPE-B mRNA was unaltered or 
decreased in striato-nigral MSNs
110,111
. The pronounced upregulation of ENKs in striato-
pallidal MSNs can cause a compensatory down-regulation of both MOP and DOP receptors in 
their target cells
112
. This is consistent with the finding that prolonged activation of MOP and 
DOP receptors by opioid ligands (i.e., ENKs) promotes their proteolytic degradation, a 
process that contributes to homeostatic regulation of cellular responsiveness to opioids
113
. 
 
Dopamine and DOP receptor transmission 
DOP receptor agonists have many stimulant-like properties in vivo. Indeed, it has been shown 
that DOP receptor agonists induce hyperlocomotion
114
 and place preference
115
. Despite these 
stimulant-like properties, the nonpeptidic DOP receptor agonist SNC-80 is not self-
administred by monkeys
37
 and does not facilitate intracranial self-stimulation
116
. Consistent 
with these behavioral findings, systemic administration of SNC-80 fails to promote DA efflux 
directly from rat striatum
117
 and does not increase extracellular DA levels in the CPu or NAcc 
assessed by microdialysis
118
. In addition to direct stimulant-like actions of DOP receptor 
agonists there is considerable evidence that DOP receptor activity can influence the actions of 
psychomotor stimulants in a variety of behavioral paradigms. For example, blocking DOP 
receptors with the antagonist naltrindole (NTI) attenuates some of the behavioral effects of 
amphetamine and cocaine, suggesting that endogenous DOP receptors signaling may 
modulate stimulant activity
119-122
. In addition, DOP receptor activation with agonists such as 
SNC-80 and TAN-67 can enhance the discriminative effects of stimulants in rats and 
monkeys
37,123-125
, increase methamphetamine-induced injurious behavior
126
 and significantly 
enhance amphetamine and cocaine-stimulated locomotor activity
117
. Consistent with the 
latter, DOP receptor agonists augment amphetamine-stimulated DA release from rat striatal 
slices
117
. The mechanisms by which DOP receptor activation with endogenous or exogenous 
ligands influences psychostimulant function is unknown. 
The disruption of DOP receptor function modifies learning and memory abilities in mice, 
suggesting a key role for DOP receptors in modulating hippocampal- and striatum-dependent 
behaviors, and further revealing potential neural substrates engaging DOP receptors in these 
processes 
127
. In the striatum DOP receptors are prominently expressed in cholinergic 
interneurons and inhibit their activity
128-130
.  
A small proportion of these receptors is also detected in GABAergic interneurons
130
 or pre-
synaptic glutamatergic terminals
131
. Consequently DOP receptors have multiple potential 
effects on striatal function. DOP receptor knockdown in cholinergic interneurons should 
facilitate their depolarization and subsequent acetylcholine release. Disinhibiting cholinergic 
15 
interneurons, however, was demonstrated to bias striatal networks towards increased 
striatopallidal activity
132
; removal of DOP receptor tone in GABAergic interneurons and/or 
glutamatergic terminals may, therefore, underlie facilitated striatal function. Up-regulation of 
ENK transmission along the striato-pallidal pathway is thought to play a crucial role in 
maintaining motor function under parkinsonian conditions. To support the view that such up-
regulation is compensatory in nature
47
, DOP receptor agonists promoted movement and 
attenuated parkinsonian-like motor deficits in rodent and non-human primate models of 
PD
47,52,133,134
. 
Finally, the notion that DOP receptors have neuroprotective activity is currently being 
examined
135
; indeed, deprivation of oxygen and blood supply induced neuronal death, and 
DOP opioid receptor activation seem to be beneficial in situations of ischemia or hipoxia
136
. 
In addition, in 1999 Borlongan and colleagues
137
 reported that DADLE could be used as a 
supplement factor for improving the cell viability of fetal mesencephalic cells and as a 
protective agent against neurotoxicity in a cell PD model. 
 
Dopamine and N/OFQ-NOP receptor system 
The widespread anatomic distribution of the N/OFQ-NOP receptor system
68,138-143
 suggests its 
involvement in a broad array of neurologic functions. N/OFQ and the NOP receptor are 
moderately to heavily expressed in DA-rich areas such as the VTA, substantia nigra pars 
compacta (SNc), and prefrontal cortex (PFC)
143,144
. N/OFQ is, therefore, in a position to 
influence DA neuronal activity and several studies have shown a functional interaction 
between these two systems. N/OFQergic transmission was found to be upregulated in the SNr 
145
, following DA receptor blockade or loss of nigral DA neurons (6-OHDA lesioning). At the 
same time, loss of nigro-striatal DA inputs causes striatal N/OFQ expression to drop. 
NOP receptor antagonists have been shown to increase motor performance in naïve and 
parkinsonian rats
146-148
 and mice
147,149
. Preliminary evidence has pointed to the involvement 
of mesencephalic DA neurons in the motor responses to NOP receptor ligands. Indeed, 
exogenous N/OFQ-induced hyperlocomotion was prevented by haloperidol
150
 or DA 
synthesis inhibitor
151
, whereas N/OFQ-induced hypolocomotion was accompanied by a 
inhibition of striatal DA release
146
. Likewise, hyperlocomotion induced by low J-113397 was 
accompanied by a facilitation of striatal DA release
146
 while hypolocomotion induced by high 
doses of J-113397 was reversed by the D2/D3 receptor antagonist amisulpride
152
. N/OFQ was 
shown to suppress striatal DA release from VTA
153
 and SNc
146
 as well as locomotor 
activity
5,150,154,155
. On the other hand, MOP receptor agonists stimulate DA release indirectly, 
through inhibition of intranigral
156
 or intra-VTA
157
 GABAergic interneurons. 
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Targeting protein- protein interaction 
One of the most essential components of cellular processes are protein- protein interactions 
(PPIs). The binding between two or more proteins in a cell can have a wide array of effects: 
modulation or initiation of signal transduction, regulation of patterns of gene transcription, 
stabilization of cytoskeletal structures, and stimulation of cellular replication or death. The 
cellular network of PPIs could contain many potential sites for drug targeting. Indeed, in the 
past years, much effort has been focused on the identification of specific inhibitors of PPIs. 
Currently, there are a number of clinically relevant therapies that target PPI interfaces. Most 
currently used PPI inhibitors (PPIIs) in the clinic are based upon humanized monoclonal 
antibodies. While this class of therapeutics possesses some very desirable properties (e.g. high 
specificity, low toxicity), it also shows several limitations that make this approach less 
promising for the widespread development of PPIIs (e.g. lack of cell/blood-brain barrier 
permeability, poor oral bioavailability, high cost of manufacture). 
The CNS is, in particular, ripe for pharmacological targeting of protein-protein interactions. 
This is due, in part, to the fact that the highly organized nature of CNS signal transduction 
relies heavily on localization and compartimentalization of signaling functions. Blocking the 
protein-protein interactions underlying this compartimentalization might provide more subtle 
tissue-specific therapeutic actions that would be achieved by blocking the signal pathway 
itself. Furthermore, highly specific neural transcriptional patterns of regulatory molecules, 
e.g. Regulators of G Protein Signaling (RGS) proteins, provide great opportunities for cell-
type selective modulation of signaling. 
 
RGS proteins 
In the conventional model of GPCR activation, the interaction between the ligand and the 7-
TM receptor catalyzes guanine nucleotide exchange on the Gβγ-complexed (and GDP-bound) 
Gα subunit. The α-GTP and the βγ of the heterodimer dissociate, and are thus free to 
propagate the signal forward via separate (and sometimes converging) interactions with 
adenyl cyclases, phospholipase-C isoforms, potassium and calcium ion channels, guanine-
nucleotide exchange factors (GEFs) for the GTPase RhoA (“RhoGEFs”), and other effector 
enzymes. The Gα subunit resets the cycle by forming Gα-GDP which has low affinity for 
effectors but high affinity for Gβγ; thus, the inactive GDP-bound heterodimer is capable once 
again of interacting with the activated receptor. In this cycle, the duration of heteromeric G-
protein signaling is controlled by the lifetime of the Gα subunit in its GTP-bound state. 
The G protein pathways are regulated by a number of proteins including scaffolding proteins 
such as RGS proteins, G protein coupled receptor kinases (GRKs), and arrestins. These 
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proteins are critical for the proper temporal and spatial regulation of GPCR signaling, and 
allow for a more finely tuned GPCR signaling for therapeutic purposes. 
The importance of RGS proteins in GPCR signal was first appreciated in studies on yeast 
(Saccharomyces cerevisiae)
158
 and nematode worms (Coenorhabditis elegans)
159
. The yeast 
RGS gene Sst2 was identified in the 1980s following an arrest in the G1 to S phase transition 
in the cell cycle during a genetic screen for mutants; similarly, the C. elegans RGS gene EGL-
10 was identified in a genetic screen. Analysis of the polypeptide sequence of EGL-10 and 
Sst2
159,160
  revealed a shared region of ~120 amino acids that was also present in several 
mammalian proteins with previously unrecognized biochemical functions, for example, the T-
cell activation immediate-early gene G0S8, now known as RGS2
161
. This ~120 amino acids 
region (the RGS domain or RGS-box), which is present in EGL-10, Sst2, RGS2 and other 
members of the RGS-protein superfamily, binds directly to the GTP-bound Gα subunit to 
markedly accelerate its rate of GTP hydrolysis and hence the rate of inactivation of GPCR 
signaling. Indeed, the RGS proteins are best known as GTPase-accelerating proteins (GAPs) 
for Gα subunits (Fig. 2). The discovery of these proteins resolved the timing paradox of how 
rapid regulation of GPCR signaling could occur given the slow rate of GTP hydrolysis by 
purified Gα subunits.  
 
 
Figure 2. Standard model of the guanine nucleotide cycle governing 7TM receptor-mediated activation of 
heterotrimeric G protein-coupled signaling. The Gβγ heterodimer serves to couple Gα to the receptor and also to 
inhibit its spontaneous release of GDP (i.e., acting as a guanine nucleotide dissociation inhibitor or “GDI” for 
Gα162,163). Ligand-occupied, 7TM cell-surface receptors stimulate signal onset by acting as guanine nucleotide 
exchange factors (GEFs) for Gα subunits, facilitating GDP release, subsequent binding of GTP, and release of 
the Gβγ dimer. Both the GTP-bound Gα and liberated Gβγ moieties are then able to modulate the activity of 
various enzymes, ion channels, and other effectors. Regulator of G-protein signaling (RGS) proteins stimulate 
signal termination by acting as GTPase-accelerating proteins (GAPs) for Gα, dramatically enhancing their 
intrinsic rate of GTP hydrolysis (taken from Siderovski and Willard
164
). 
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There are over twenty identified proteins in the mammalian RGS family, which share a 
common catalytic “RGS domain” but differ in structure, substrate specificities and tissue 
distribution
165,166
. They interact with limited selectivity for most Gα subtypes, the only 
exception being Gαs, for which no RGS interaction has been confirmed. According to the 
similarity in sequence and features of structural domains, RGS proteins have been classified 
into nine subfamilies (Tab. 2). These molecules are more than just Gα GAPs167,168. For 
example, there is an RGS-box in the amino terminus of p115-RhoGEF, a known GEF for the 
monomeric G protein RhoA, which functions as a signaling bridge between GPCRs and 
RhoA
169
. Small-molecule inhibitors of the RhoGEF RGS-box that block G13α binding should 
reduce GPCR-mediated activation of RhoA and its downstream signaling pathways, which 
are involved in cellular transformation and metastatic progression. 
There are at least three ways in which specificity of RGS-protein action can arise. First, at the 
molecular level, RGS proteins have specificity for discrete Gα subfamilies, and there is an 
increasing evidence for selective RGS-protein modulation of particular receptor actions. 
Second, each tissue expresses a distinct repertoire of RGS proteins. Finally, RGS proteins can 
be differentially up- or downregulated by physiological signals or pathological conditions, 
which can provide state-dependent specificity
170
. 
There are increasing reports of RGS selectivity for specific GPCRs, suggesting that targeting 
a RGS may provide a mechanism to selectively regulate signaling through a particular 
GPCR
171,172
. 
Genetic ablation of RGS activity either by deletion of a particular RGS gene or by expression 
of RGS-insensitive Gα subunits has dramatic physiological consequences173. For example, 
RGS4-deficient mice display increased sensivity to carbachol-potentiated, glucose-stimulated 
insulin release. Deletion of RGS9 produces a variety of neurological effects, including 
sensitization to morphine analgesia and reward, with decreased tolerance deficits in working 
memory, and motor coordination defects
174,175
. Knock-in mice, expressing a mutant Gαi 
subunit which was unable to interact with RGS proteins
176
, show dramatic phenotypes, 
including spontaneous antidepressant-like effects as well as resistance to diet-induced 
obesity
177,178
. Thus, targeting a specific RGS protein and inhibiting protein-protein 
interactions, such as that between RGS and Gα subunit, may open new therapeutic strategies. 
In particular, molecules that are able to disrupt the RGS-Gα interaction should increase the 
magnitude and/or duration of G-protein signaling responses, leading to pronounced 
physiological effects. 
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Subfamily Members Representative protein structures Common feature 
outside RGS domain 
RZ/A GAIP/RGS19 
RGSZ1/RGS20 
RGSZ2/RGS17 
Ret-RGS1 
 
                       Poly-Cys
___RGS___ 
N-terminal cysteine string 
R4/B RGS1,RGS2,RGS
3,RGS4,RGS5,R
GS8,RGS13,RGS
16,RGS18,RGS21 
 
                             helix≈__RGS___ 
N-terminal amphipatic α-
helix, or without any 
specified domains 
R7/C RGS6,RGS7, 
RGS9,RGS11 
 
_DEP_GCL___RGS___ 
N-terminal DEP and GGL 
domains 
R12/D RGS10,RGS12,R
GS14 
 
_PDZ_PTB___ RGS___RBD__
GoLoco
_
PDZB
 
May contain PDZ, PTB, 
RBD, GoLoco, and PDZ-
binding, β-catenin binding, 
PP2A homology, and 
dimerization domains DH 
and PH domains 
RA/E Axin,Conductin ___RGS___GSK__β-Cat__PP2A__D 
GEF/F P115-RhoGEF 
PDZ-
RhoGEF,LARG 
 
               ___RGS___DH__PH 
GRK/G GRK1,GRK2,GR
K3,GRK4,GRK5,
GRK6,GRK7 
 
              ___RGS___Kinase__PH 
GPCR kinase and PH 
domains 
SNX/H RGS-
PX1(SNX13),SN
X14,SNX25 
 
                ___PXA___RGS__PX 
(Gsα–specific RGS domain), 
PXA and PX domains 
D-AKAP2/1 D-AKAP2                 ___RGS___RGS__
PXA-anchor
 (Two RGS domains) 
 
β-Cat, β-catenin-binding; D, dimerization domain: D-AKAP, dual-specifocoty A-kinase anchoring protein; DEP, disheverlled/EGL-
10/pleckstrin; DH, double homology; GEF, guanine nucleotide exchange factor; GGL, Gγ-like; GoLoco, Gαi/o-Loco; GRK, G protein-
coupled receptor kinase; GSK. Glycogen synthase kinase 3β-binding; PDZ, PSD95/Dlg/Z0-1/2; PH, pleckstrin homology; PP2A, protein 
phosphatase 2A; PTB, phosphotyrosine-binding; PX, phosphatidylinositol-binding; PXA, PX-associated; RBD, Ras-binding domain; SNX, 
sortin nexin. 
Tab. 2. Classification of RGS proteins subfamilies and their structural features (taken from Xie and Palmer
179
). 
 
RGS4 as a new drug target 
RGS4 is one of the most extensively studied RGS proteins. RGS4 is a relatively small protein 
of simple structure, in which the N-terminal domain discriminates among receptor signaling 
complexes. Accordingly, deletion of the N-terminal domain of RGS4 eliminated receptor 
selectivity and reduced potency by 10
4
-fold
180
. It attenuates the intensity and duration of Gαi/0 
and Gαq/11 subunits-coupled receptor signaling 
181,182
 and is involved in many clinical 
diseases. Genetic studies indicate that RGS4 is a vulnerability factor for schizophrenia
183,184
. 
In addition, RGS4 plays important roles for dopaminergic control of striatal long-term 
depression, susceptibility to Parkinson’s disease185 and neural plasticity186. 
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RGS4 is highly expressed in the brain and robustly distributed in regions that are involved in 
the response to drugs of abuse and cognition processes. These regions include the prefrontal 
cortex, striatum, hippocampus and locus coeruleus
165,187
. In vitro and genetic studies have 
linked RGS4 to the regulation of µ-opioid receptor signaling and supported its role in 
morphine reward and physical dependence
188-190
. Indeed, GPCR and their downstream 
signaling partners play a crucial role in the activation of gene expression in the striatum after 
acute exposure to psychostimulants like amphetamine or cocaine. Not surprisingly, G-protein 
signaling itself is subject to tight regulation that may be disrupted in drug addiction and 
neuropsychiatric disorders
183,191-194
. Several studies suggested a potential role of RGS proteins 
in long-term adaptation processes observed in response to pharmacological treatment
195,196
 or 
occurring during the development of neurodegenerative diseases 
193
. RGS4 is known to 
regulate the signal of several Gαi-coupled receptors, such as metabotropic glutamate 
receptors
197
, opioid receptors
198,199
, and 5-HT1 receptors but probably not dopamine D2 
receptors
200
. On the other hand, D1 and D2 receptors regulate RGS4 gene expression; either 
pharmacological blockade of D1 receptors or selective stimulation of D2 receptors increases 
RGS4 gene expression in the striatum
201,202
. The tight transcriptional control to which RGS4 
is submitted pleads in favour of its potential contribution to the fine tuning of D2 signaling 
cascade. Particularly striking is that D2 agents act on pre-synaptic D2 receptors to regulate 
RGS4. This observation, together with the colocalization patterns of RGS2 or RGS4 with D1 
or D2 receptors, confirmed the roles of these RGS proteins in D1 and D2 signaling. 
Moreover, the rapid transient regulation of RGS2 mRNA and delayed transient regulation of 
RGS4 mRNA suggest that synergistic compensations in DA signaling potentially mediated by 
this RGS are temporally additive
203
. 
The effects of RGS proteins on opioid receptors have been examined in several systems. The 
findings are not always consistent, probably due to the different methodologies used. It has 
been shown that members of the RZ, R4 and R7 subfamilies
204
 of RGS proteins play crucial 
roles not only in terminating acute opioid agonist action but also in opioid receptor 
desensitization, internalization, recycling, and degradation
199,205
, thereby affecting opioid 
tolerance and dependence
206,207
. Much work has been performed with RGS4, because of its 
small structure and its wide distribution in the brain, especially in brain regions important for 
opioid actions. In vitro, RGS4 has been shown to reverse DOP receptor agonist induced 
inhibition of cAMP synthesis in membranes prepared from NG108-15 cells
182
, and 
overexpression of RGS4 in HEK293 cells also attenuates morphine-, DAMGO, and DPDPE-
induced inhibition of adenylyl cyclase
208,209
. These and other previous studies have provided 
evidence that RGS4 can negatively regulate opioid receptor signaling in transfected systems; 
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moreover Wang and colleagues
210
, using a short hairpin RNA (shRNA) to reduce the 
expression level of RGS4, showed that changes in DOP but not MOP receptor-mediated 
signaling occur. This finding argued in favor of a selective interaction of RGS4 with the DOP 
receptor. Indeed, co-immunoprecipitation studies by the same group indicated that the DOP 
but not the MOP receptor is closely associated with RGS4, providing further evidence for a 
selective interaction between RGS4 and the DOP receptor. Indeed, RGS4 interacts directly, 
probably through its N-terminal region
211
, with the GST fusion proteins of the C-tail and the 
third intracellular loop of the DOP receptor but only interacts with the GST-fusion C-terminal 
tail peptides of the MOP receptor
198
. On the other hand, it was hypothesized also an indirect 
interaction between the DOP receptor and RGS4
212
, perhaps mediated by an intermediate 
scaffold, such as spinophillin. Spinophillin is known to bind to several GPCR at the third 
intracellular loop and to RGS4
213
. Given that RGS4 is widely expressed in many brain 
regions
165
, including the amygdala, NAcc, and caudate-putamen, where DOP receptors are 
also highly expressed
10
, the selective RGS4 modulation of DOP receptor signaling may play a 
significant role in modulation of DOP receptor-mediated behaviors. 
 
RGS4 inhibitors 
The development of small molecule inhibitors of RGS proteins has been pursued due to their 
strong modulatory role in GPCR signaling
214-216
 and possibly therapeutic potential. The 
localized expression of these proteins allows to achieve tissue specificity for GPCR agonist 
actions
170,216,217
; furthermore, the rationale for targeting RGS4 relies on the up-regulation of 
this protein in various diseases, for example, in neuropathic pain models
208
. 
The GTPase accelerating activity of RGS4 is regulated by phosphatidylinositol 3,4,5-
triphosphate at a site far away from the Gα interaction interface218,219 (“B” site). Targeting this 
allosteric site
217
, might be a more tractable approach for inhibiting the RGS-Gα protein-
protein interaction than attempting to orthosterically occlude the protein-protein interaction
220
. 
Developing small molecules or peptide modulators of RGS proteins is a booming 
field
170,215,217,221-223
. RGS inhibitor could act as GPCR signaling potentiator. Given alone, it 
would be expected to potentiate the effects of endogenous ligands, and given with a GPCR 
agonist, it would be expected to increase its potency or selectivity. 
Most diseases resulted from changes in a complex set of signaling pathways, in which 
different RGS proteins are involved; on the other hand, the activity profile that would provide 
the best effect for one disease, may not be suitable for another disease. So while still 
hypothetical, it is possible to imagine that an inhibitor with a specific set of activity against 
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different RGS proteins or a combination of two or more inhibitors with specific targets might 
be valuable in the treatment of certain disease. 
Two different groups published independent series of peptide inhibitors of RGS4 functions. 
The first series was designed to mimic the switch I region of Gαi
224,225
; the second series was 
developed by a random yeast-two hybrid screening campaign
226
. The peptides derived by 
these two series had modest (mid-low micromolar) activity on both binding and functional 
assays. The first small molecule inhibitor of RGS4 was published in 2007
227
. This compound, 
CCG-4986 (4-chloro-N-[N-4-nitrophenyl)methoxysulfanyl]benzene-1-sulfonamide), was 
identified through a flow-cytometry protein interaction assay (FCPIA)-based high throughput 
screen on a diverse compound library. CCG-4986 has a 4 μM IC50 value for the inhibition of 
RGS4 binding to Gα0, and shows significant selectivity for RGS4 over RGS8, its closest 
relative based upon sequence homology. The GTP hydrolysis assay also confirmed the 
activity of this compound: CCG-4986 blocked GAP activity of RGS4. It is able to form 
irreversible covalent adducts with the RGS in both orthosteric (i.e. at the site of Gα 
binding)
228,229
 and allosteric interaction sites
229
. There is a limit in the use of CCG-4986 as a 
pharmacological tool, because it does not function in a cellular environment, but the 
development of this compound and the evidence that it is able to inhibit RGS and also to 
produce allosteric modulation, may provide greater specificity among RGS proteins. 
Other limits related to the use of CCG-4986 regard its irreversibility and its inactivation in 
presence of reducing agents
228,229
; for these reasons several studies attempted to identify new 
compounds that act reversibly and retain substantial function in the presence of glutathione, a 
predominant intracellular reductant. In 2010, Blazer and colleagues described the first set of 
compounds that can reversibly inhibit RGS4. The prototypical compound of this class, CCG-
63802, has an in vitro IC50 value of 10 μM in the FCPIA assay. Specifically, mutagenesis 
studies predict that the binding of CCG-63802 to the “B” site of RGS4 is able to induce a 
conformational change; the “B” site of RGS4 is an important location for the binding of 
calmodulin and acidic phospholipids, which reciprocally regulate RGS GAP activity, 
whereby phospholipid binding inhibits the RGS function and this effect can be displaced by 
calmodulin
218,230
. Despite this family of compounds provided the first proof-of-concept that 
RGS proteins can be inhibited by small molecules in a reversible fashion, they do not appear 
to possess significant cellular activity. For this reason, even if the “B” site hypothesis has 
been studied from different functional angles, there are no data that specifically address how 
this allosteric binding results in altered GAP activity. A suitable compound to examine in 
depth this hypothesis needs to have a greater potency at RGS4 (~2 Log more potent than 
CCG-63802) and to show a smaller polar surface area than CCG-63802 to improve membrane 
23 
permeability. The CCG-50014 class of compounds includes molecules with documented 
cellular activity. CCG-50014 is the most potent small molecule RGS inhibitor, it irreversibly 
inhibits RGS4 over RGS proteins (including RGS7, RGS8, RGS16 and RGS19) with a 30 nM 
IC50 value. While irreversible, this compound provides the basis for studying the molecular 
mechanisms of RGS allosteric inhibition. 
In the present study, we used CCG-203769, which is a member of the class of compounds 
derived from CCG-50014, and has been synthetized by Dr. Neubig and his coworkers at the 
University of Michigan. CCG-203769 and correlated molecules act by inhibiting both the 
RGS/Gα PPI and RGS activity in a living cell and have a greater aqueous solubility than 
CCG-50014; moreover, their action has a measurable effect upon GPCR signaling. 
Previous studies demonstrated that in β cells, M3 receptor activation potentiates glucose-
stimulated insulin release
231
 and that this event is under RGS4-control
232
. Using isolated 
mouse islets, Blazer and colleagues attempted to determine if CCG-50014 and CCG-203769 
were able to enhance the M3 activity on glucose-stimulated insulin release with promising 
preliminary data. 
Both the CCG-63802 and the CCG-50014 classes of molecules could help provide further 
information on the location and the geometry of small molecules binding sites on RGS4 and 
to study the effects of RGS protein in vivo. 
New compounds derived from these classes could be useful research tools and may 
potentially have relevant therapeutic roles. 
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Purpose 
 
This study is based on the evidence that the opioidergic system markedly contributes to the 
physio-pharmacological regulation of the motor function. The overall goal of the study was to 
investigate the mechanisms underlying the motor responses to opioid receptor ligands, in 
particular the contribution of endogenous DA, and of intra-cellular modulators of the opioid 
receptors.  
Essentially, we investigated whether different DA receptor subtypes, more specifically, pre- 
and post-synaptic D2 receptors, were differentially recruited in motor responses to NOP and 
DOP receptors agonists and antagonists, and tested the hypothesis that inhibition of RGS 
proteins, could amplify the motor actions of DOP receptor agonists. 
To achieve these aims, in the first part of this work, we undertook a combined 
pharmacological and genetic approach, using selective DA receptor antagonists, and mice 
carrying genetic deletions of the D2 receptor (D2R
-/-
)
233
, or its long (post-synaptic) isoform 
(D2L
-/-
)
234
. These data point to the involvement of D2 receptors in the motor actions of NOP 
receptor ligands, further suggesting that post-synaptic and pre-synaptic D2 receptor 
subpopulations may mediate motor facilitation and motor inhibition induced by low and high 
doses of NOP receptor ligands, respectively (part 1). 
Using the same genetic approach, D2R
-/-
 and D2L
-/-
 mice were next used to dissect out the 
role of pre- and posts-ynaptic D2 receptors in the motor actions of DOP receptor ligands. The 
results indicate that genetic removal or pharmacological blockade of post-synaptic D2 
receptors disclose a motor promoting action of DOP receptor ligands, suggesting the 
existence of a negative D2/DOP receptor interaction both at the membrane and network level. 
As D2R
-/-
 mice have been considered a model of PD, this data suggested that the 
antiparkinsonian actions of DOP receptor agonists are DA-independent (part 2). 
In the third part of this study, we used a selective small molecule inhibitor, CCG-203769 
(provided by Dr R Neubig, University of Michigan), to disclose the role of RGS4 on motor 
activity in parkinsonian conditions, and investigate whether RGS4 blockade could amplify the 
antiparkinsonian response to DOP receptor ligands. We found that CCG-203769 reversed 
neuroleptic-induced parkinsonism, and rescued stepping activity in 6-OHDA hemilesioned 
mice and 6-OHDA hemilesioned rats, also producing a synergistic beneficial symptomatic 
response when given in combination with a DOP agonists. These data suggest that RGS4 
might be a novel therapeutic target in PD (part 3). 
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Materials and methods 
 
Animals 
All animals used in this study were housed with free access to food and water and kept under 
environmentally controlled conditions (12-h light/dark cycle with light on between 07:00 and 
19:00). The experimental protocols were approved by the Italian Ministry of Health (licenses 
n. 94/2007B and 194/2008B) and Ethical Committee of the University of Ferrara. Adequate 
measures were taken to minimize animal pain and discomfort. 
 
Mice 
Young male (20-25 g; 8-9 weeks old) C57BL/6J mice, 129/Sv/C57BL6J D2R
+/+
 and D2R
-/-233
 
and 129/Sv/C57BL6J D2L
+/+
 and D2L
-/-234
 were used in this study. C57BL/6J mice were 
purchased from Harlan Italy (S. Pietro al Natisone, Italy), while genetically modified mice 
were provided by Emiliana Borrelli (University of California, Irvine). 
 
Rats 
Young adult male (120-125 g; 12-13 weeks old) Sprague-Dawley were used in this study. 
Rats were purchased from Harlan Italy (S. Pietro al Natisone, Italy). 
 
Lesion of the DA system 
In order to lesion the DA neurons located in SNc and deplete striatum of DA, different 
protocols were used. All lesion procedures led to an unilateral massive destruction of the 
nigrostriatal DA projection. 
 
6-OHDA lesion in C57BL/6J mice 
Mice were anaesthetized with a mixture of isoflurane and air, and secured in a stereotaxic 
frame. Unilateral lesion of nigral DA neurons was induced by injecting 6-OHDA (Tocris 
Bioscience, Bristol UK), dissolved in 0.02% ascorbate saline at the concentration of 3.0 μg/μl 
freebase 6-OHDA. Mice received 2 injections X 2 μl 6-OHDA into the striatum at the 
following coordinates from bregma: (i) AP= +1.0, ML =−2.1, DV= −2.9; (ii) AP= +0.3, ML = 
−2.3, DV= −2.9235, as previously described236. In order to assess the efficacy of the lesion, all 
mice were tested for spontaneous rotation and for akinesia/bradykinesia (bar and drag tests) 
10 days after lesion. 
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6-OHDA lesion in rats 
Unilateral lesion of nigro-striatal DA neurons was induced in isoflurane-anaesthetised rats
145
 
by stereotaxically injecting 8 µg of 6-OHDA (in 4 µl of saline containing 0.02% ascorbic 
acid) in the right medial forebrain bundle (MFB) according to the following coordinates from 
bregma: AP= -4.4 mm, ML= -1.2 mm, DV= -7.8 mm below dura
237
. 
 
Drug-induced rotation 
The rotational model
238
 was used to select the rats which had been successfully lesioned with 
6-OHDA. Two weeks after lesion, rats were injected with amphetamine (5 mg/Kg i.p., 
dissolved in saline) and only those rats performing >7 ipsilateral turns/min were enrolled in 
the study. This behavior has been associated with >95% loss of striatal extracellular DA 
levels
239
. 
 
Behavioral studies 
Motor activity in rodents was evaluated by means of different behavioral tests (bar, drag and 
rotarod test) specific for different motor abilities, as previously described
145
. The different 
tests are useful to evaluate motor functions under static or dynamic conditions. Two features 
that are analyzed are akinesia and bradykinesia. Akinesia appears as an abnormal absence or 
poverty of movements, that is associated in hemilesioned mice and rats to the loss of the 
ability to move the forepaw when placed on blocks at different heights (bar test). 
Bradykinesia is referred to slowness of movement and in particular to difficulties of adjusting 
its position in response to backwards dragging (drag test). The battery of tests described 
below, can be used to assess the degree of bradykinesia and akinesia of the animals, 
representing important behavioral correlates of parkinsonian symptoms. We performed these 
tests in a fixed sequence (bar test, drag test, and rotarod test). 
 
Bar test 
This test, also known as the catalepsy test
240
, measures the ability of the animal to respond to 
an externally imposed static posture. Each rodent was placed gently on a table and the right 
and left forepaws were placed alternatively on blocks of increasing heights (1.5, 3 and 6 for 
mice and 3, 6 and 9 for rats). The immobility time (in sec) of each forepaw on the blocks was 
recorded (cut-off time 20 sec per step, 60 sec maximum). Akinesia was calculated as total 
time spent on the blocks by each forepaw. 
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Drag test 
The test (modification of the “wheelbarrow” test241), measures the ability of the animal to 
balance its body posture using forelimbs in response to an externally imposed dynamic 
stimulus (backward dragging
145
). Each rodent was gently lifted by the tail (allowing the 
forepaws on the table) and dragged backwards at a constant speed (about 20 cm/sec) for a 
fixed distance (100 cm). The number of touches made by each forepaw was counted by two 
separate observers (mean between the two forepaws). 
 
Rotarod test 
This test analyzes the ability of the rodents to run on a rotating cylinder (diameter 8 cm) and 
provides information on different motor parameters such as coordination, gait, balance, 
muscle tone and motivation to run
242
. The fixed-speed rotarod test was employed according to 
a previously described protocol
146,149,152
. Briefly, animals were tested at stepwise increasing 
speeds (180 sec each) and time spent on the rod calculated (in sec). 
 
Data presentation and statistical analysis 
Data are expressed as means ± SEM of n determinations per group or as percentages of the 
control sessions. Different statistical analyses were performed, as appropriate, using the 
Student’s t test, one-way repeated measures (RM) ANOVA followed by the Newman-Keuls 
test or the Bonferroni’s multiple comparisons test. P values <0.05 were considered to be 
statistically significant. 
 
Drugs 
6-OHDA hydrobromide, amisulpride, raclopride, SCH23390 and SNC-80 were purchased 
from Tocris Bioscience (Bristol, UK). S33084 was provided by Institut de Recherches Servier 
(Croissy-sur-Seine, France). N/OFQ and J-113397 were synthetized in the laboratories of the 
Department of Pharmaceutical Chemistry at the University of Ferrara. CCG-203769 was 
provided by Dr. Richard Neubig (University of Michigan). All drugs were freshly dissolved 
in the vehicle just prior to use. 
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Results 
 
Part 1. Role of endogenous DA in the motor action exerted by NOP receptor ligands. 
In the first part of the present study we investigated the motor profiles of NOP receptor 
ligands in C57BL/6J mice, using static and dynamic tests providing complementary 
information on motor parameters: the bar, drag and rotarod test. Then, to evaluate the 
contribution of the various DA receptor subtypes in the motor action of NOP receptor ligands, 
we used selective DA receptor antagonists and analysed the impact of sub-threshold doses of 
these antagonists on the motor effects of NOP receptor ligands. These experiments revealed 
the involvement of D2 receptors in the motor responses to NOP receptor ligands, and 
suggested that different D2 receptor subpopulations might mediate motor facilitation and 
inhibition observed with the lower and high doses of the NOP antagonist J-113397. To 
confirm pharmacological data we adopted a genetic approach, by testing N/OFQ and the NOP 
receptor antagonist J-113397 in D2 knockout mice. 
 
 
1.1 The NOP receptor antagonist J-113397, and exogenous N/OFQ dually modulated 
motor activity. 
Basal activity of C57BL/6J mice was 0.8 ± 0.1 sec (immobility time in the bar test), 16.5 ± 
0.9 steps (drag test) and 937 ± 62.1 sec (time on rod). J-113397 increased the immobility time 
(i.e. inhibited movement initiation) in the bar test at the highest dose tested (10 mg/Kg) (Fig. 
1A) and dually modulated stepping activity and rotarod performance (Fig. 1B and C), causing 
facilitation at low doses (0.3-1 mg/Kg) and inhibition at higher doses. 
Since data obtained with the NOP antagonist suggested a dual regulation of motor activity by 
endogenous N/OFQ, we investigated whether exogenous N/OFQ could replicate this pattern. 
N/OFQ, given i.c.v., monotonically increased immobility time from 0.1 nmol onwards (Fig. 
2A). Conversely, it dually regulated stepping activity and rotarod performance (Fig. 2B and 
C), causing motor facilitation at 0.01 nmol and motor inhibition at 0.1-10 nmol. 
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Fig. 1. J-113397 dually modulated motor activity in C57BL/6J mice. Systemic administration of J-113397 (0.1-
10 mg/Kg, i.p.) affected motor performance in the bar (A), drag (B) and rotarod (C) tests. All tests were 
performed before (control session) and after (10 min) drug injection. Data are means ± SEM of 6 determinations 
per group and were expressed as percentage of the control session. *p<0.05, p**<0.01 different from saline 
(one-way ANOVA followed by the Bonferroni test). 
 
 
Fig. 2. N/OFQ dually modulated motor activity in C57BL/6J mice. I.c.v. injection of  N/OFQ (0.1-30 nmol) 
affected motor performance in the bar (A), drag (B) and rotarod (C) tests. All tests were performed before 
(control session) and after (10 min) N/OFQ injection. Data are means ± SEM of 6 determinations per group and 
were calculated as percentage of the control session. *p<0.05, p**<0.01 different from saline (one-way ANOVA 
followed by the Bonferroni test). 
 
1.2 Dopamine receptor antagonists differentially modulated motor actions of NOP 
receptor ligands. 
The D1/D5 (SCH23390), D2/D3 (raclopride and amisulpride) and D3 (S33084) receptor 
antagonists were administered to C57BL/6J mice to evaluate the contribution of various DA 
receptor subtypes in the motor action exerted by NOP receptor ligands. The D2/D3 receptor 
antagonist raclopride, given alone (0.03-0.3 mg/Kg, i.p.), caused a dose-dependent and long-
lasting elevation of immobility time, and reductions in the number of steps and time on 
rotarod (Fig. 3A-C). Amisulpride replicated the motor inhibiting action of raclopride in the 
bar and rotarod test (5-15 mg/Kg, i.p.) but did not affect the stepping activity in the drag test 
(Fig. 3A-C). The D1/D5 antagonist SCH23390 produced consistent motor inhibition in all 
three tests, being effective at 0.01 mg/Kg (i.p.) (Fig. 3A-C), whereas the D3 antagonist 
S33084 did not produce any marked changes in motor activity; the only effect observed was a 
mild inhibition of stepping at 0.64 mg/Kg (i.p., Fig. 3B). 
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We then selected doses of DA receptor antagonists that did not produce effect on motor 
activity, and analysed their impact on the motor effects of NOP receptor ligands. Low doses 
of N/OFQ or the NOP receptor antagonist J-113397 were ineffective in the bar test, both in 
the absence and in the presence of DA receptor antagonists (Fig. 4A). Raclopride (0.03 
mg/Kg) prevented the increase in stepping activity (Fig. 4B) and rotarod performance (Fig. 
4C) induced by J-113397 (0.3 mg/Kg), Whereas amisulpride (0.5 mg/Kg), SCH23390 (0.003 
mg/Kg) and S33084 (0.16 mg/Kg) were ineffective (Fig. 4B-C). Raclopride also prevented 
the motor facilitation induced by the low dose of N/OFQ (0.01 nmol) (Fig. 4A-C). On the 
other hand, motor inhibition induced by high doses of the NOP receptor antagonist J-113397 
(10 mg/Kg) in the bar (Fig. 5A), drag (Fig. 5B) and rotarod (Fig. 5C) tests was prevented by 
amisulpride but not by raclopride (Fig. 5A-C). In the drag and rotarod tests, amisulpride 
reversed motor inhibition induced by J-113397, resulting in long-lasting stimulation (Fig. 5B 
and C). These data suggest the involvement of D2 receptors in the motor actions exerted by 
the NOP receptor antagonist J-113397. Considering the different responses to raclopride and 
amisulpride, we also speculate that different D2 receptor subpopulations might mediate motor 
facilitation and motor inhibition observed with lower and high doses the NOP antagonist. To 
dissect out the contribution of pre- and post-synaptic D2 receptors on the motor profile of 
NOP receptor ligands we undertook a genetic approach. 
 
 
Fig. 3. DA receptor antagonists impaired motor activity in C57BL/6J mice. Administration of the D2/D3 
receptor antagonists raclopride (0.03-0.3 mg/Kg, i.p.) and amisulpride (0.5-15 mg/Kg, i.p.), the D1/D5 receptor 
antagonist SCH23390 (0.003-0.03 mg/Kg, i.p.) and the D3 receptor antagonist S33084 (0.04-0.64 mg/Kg, i.p.) 
produced dose-dependent motor inhibition. Motor activity has been evaluated as immobility time in the bar test 
(A), number of steps in the drag test (B) and time spent on rod in the rotarod test (C). All tests were performed 
before (control session) and 30 min after drug administration. Data are means ± SEM of 6 determinations per 
group and are expressed as percentage of the control session. *p<0.05, **p<0.01 different from saline or vehicle 
(ANOVA followed by Newman Keuls test for multiple comparisons). 
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Fig. 4. Motor facilitation induced by NOP receptor ligands was selectively prevented by raclopride. Pretreatment 
with D2/D3 receptor antagonist raclopride (0.03 mg/Kg, i.p.) prevented motor facilitaton caused by low doses of 
N/OFQ (0.01 nmol, i.c.v.) or the NOP receptor antagonist J-113397 (0.3 mg/Kg, i.p.). Conversely, pretreatment 
with the D2/D3 receptor antagonist amisulpride (0.5 mg/Kg, i.p.), the D1/D5 receptor antagonist SCH23390 
(0.003 mg/Kg, i.p.) and the D3 receptor antagonist S33084 (0.16 mg/Kg, i.p.) did not affect motor facilitation 
induced by J-113397 (0.3 mg/Kg, i.p.). Motor activity has been evaluated as immobility time in the bar test (A), 
number of steps in the drag test (B) and time on rod in the rotarod test (C). All tests were performed before 
(control session) and 10 min after NOP receptor ligands administration. Data are means ± SEM of 6 
determinations per group and are expressed as percentage of the control session. **p<0.01 different from saline 
or vehicle; °°p<0.01 different from the same group in the absence of raclopride or J-113397 (ANOVA followed 
by Newman Keuls test for multiple comparisons). 
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Fig. 5. Motor inhibition induced by the NOP receptor antagonist J-113397 was selectively prevented by 
amisulpride. Pretreatment with the D2/D3 receptor antagonist amisulpride (0.5 mg/Kg, i.p.) prevented motor 
inhibition caused by high doses of the NOP receptor antagonist J-113397 (10 mg/Kg, i.p.). Pretreatment with the 
D2/D3 receptor antagonist raclopride (0.03 mg/Kg, i.p.) did not affect motor inhibition induced by J-113397 (10 
mg/Kg, i.p.). Motor activity has been evaluated as immobility time in the bar test (A), number of steps in the 
drag test (B) and time spent on the rod in the rotarod test (C). All tests were performed before (control session) 
and 10 min after J-113397 injection. Data are means ± SEM of 6 determinations per group and are expressed as 
percentage of the control session. *p<0.05, **p<0.01 different from saline or vehicle; °°p<0.01 different from 
the same group in the absence of DA receptor antagonists (ANOVA followed by Newman Keuls test for 
multiple comparisons). 
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1.3 NOP receptor ligands differentially affected motor activity in D2R
-/-
 and D2L
-/-
 mice 
D2R
-/-
 mice showed greater immobility time (5.3 ± 0.3 vs 0.2 ± 0.1 sec; p<0.0001) and lower 
number of steps (3.4 ± 0.4 vs 13.0 ± 0.8; p<0.0001) and rotarod performance (328.1 ± 42.8 vs 
888.3 ± 85.5 sec; p<0.0001) than D2R
+/+
 mice. As shown in C57BL6J mice, J-113397 
facilitated motor performance at low doses (0.3-1 mg/Kg) and inhibited it at higher ones (10 
mg/Kg) in D2R
+/+
 mice (Fig. 6A-C). Conversely, J-113397 was ineffective in D2R
-/-
 mice 
(Fig. 6A-C). Basal activity of D2L
-/-
 mice did not differ from controls in the bar (0.6 ± 0.1 vs 
0.8 ± 0.1 sec t=2.06, p=0.06) and rotarod (906.6 ± 66.9 vs 869.3 ± 36.8 sec; t=0.49, p=0.63) 
tests, although a mild reduction of stepping activity in the drag test was found (12.6 ± 0.5 vs 
15.6 ± 0.6 steps; t=3.64, p=0.0019). The motor responses of J-113397 in D2L
+/+
 mice were 
quali- and quantitatively similar to C57BL6J and D2R
+/+
 mice (Fig. 6D-F). In D2L
-/-
 mice, 
only the inhibitory effect of 10 mg/Kg J-113397 persisted unchanged, facilitation being not 
observed (Fig. 6D-F). These results suggest that the motor facilitation observed with the NOP 
antagonist J-113397 involves the post-synaptic D2L receptors, while motor inhibition appears 
to be mediated by pre-synaptic D2 receptors. 
The dual response to N/OFQ was evident in D2R
+/+
 mice where 0.01 nmol N/OFQ elevated 
stepping activity (Fig. 7B) and rotarod performance (Fig. 7C) and 10 nmol N/OFQ inhibited 
them (Fig. 7B and C). This dose also elevated immobility time in the bar test (Fig. 7A). The 
low dose of N/OFQ was ineffective in D2R
-/-
 mice, whereas the higher one was still able of 
increasing the immobility time and reducing stepping activity and rotarod performance, 
although the effect was somewhat attenuated compared to control mice (Fig. 7A-C). In 
absolute values, N/OFQ (10 nmol) increased immobility time from 5.8 ± 0.5 to 16.5 ± 2.9 sec, 
and reduced stepping activity and rotarod performance from 4.7 ± 0.2 to 2.7 ± 0.6 steps and 
from 281.3 ± 34.7 to 70.2 ± 6.8 sec, respectively. Dual response to N/OFQ was also observed 
in the drag (Fig. 7E) and rotarod test (Fig. 7F) in D2L
+/+
 mice. In D2L
-/-
 mice the low N/OFQ 
dose was ineffective whereas the high 10 nmol dose produced a quantitatively similar 
inhibition as in control mice (Fig. 7D-F). These data indicate that the motor facilitation 
induced by low N/OFQ doses is likely mediated by D2L acting at post-synaptic sites. 
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Fig. 6. J-1113397 (0.1-10 mg/Kg) increased the immobility time in the bar test (A, D), and reduced the number 
of steps in the drag test (B, E) and time spent on the rod in the rotarod test (C, F) in D2L
-/-
 mice, being 
ineffective in D2R
-/-
 mice. All tests were performed before (control session) and 10 min and after J-113397 
injection. Data are means ± SEM of 6 determinations per group and were calculated as percentage of the control 
session.. *p<0.05, **p<0.01 different from saline (ANOVA followed by Newman-Keuls for multiple 
comparisons). 
 
 
Fig. 7. Motor inhibition, but not facilitation, induced by nociceptin/orphanin FQ (N/OFQ) was detected in D2R
-/-
 
and D2L
-/-
 mice. I.c.v. injections of N/OFQ (0.01 and 10 nmol) differentially affected immobility time in the bar 
test (A, D), number of steps in the drag test (B, E) and time spent on the rod in the rotarod test (C, F) in D2R
+/+
 
(A-C) and D2L
-/-
 mice (D-F). All tests were performed before (control session) and 10 min  after N/OFQ 
injection. Data are means ± SEM of 6 determinations per group and were calculated as percentage of the control 
session.. **p<0.01 different from saline (ANOVA followed by Newman-Keuls for multiple comparisons). 
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Part 2. Influence of dopamine D2 receptors in the motor effects of DOP receptor ligands. 
The second part of the thesis was undertaken to dissect out the role of D2 pre- and post-
synaptic receptors in the motor actions of DOP receptor ligands. DOP receptor ligands, 
namely the DOP agonist SNC-80, and the DOP antagonist naltrindole (NTI), were 
administered to D2R
-/-
 and D2L
-/-
 mice, and motor performances recorded. 
 
2.1 SNC-80 reduced motor impairment in D2R
-/-
 mice, while NTI was ineffective. 
D2R
-/-
 mice showed increased immobility time (37.7±2.2 vs 7.0±1.3 sec, p<0.0001) in the bar 
test, reduced stepping activity (8.4±0.6 vs 15.5±0.6 steps, p<0.0001) in the drag test and 
reduced rotarod performance (33.6±6.2 vs 1132.0±73.7 sec, p<0.0001) compared to wild-type 
controls. SNC-80 was ineffective in D2R
+/+
 mice but improved motor function in D2R
-/-
 mice. 
SNC-80 reduced immobility time (~50%) at 10 mg/Kg (Fig. 8A) and facilitated stepping 
activity at 3 and 10 mg/Kg (~60% and ~85% respectively) (Fig. 8B and C), being ineffective on 
the rotarod performance. NTI was ineffective up to 5 mg/Kg in both genotypes (Fig. 8D-F). 
 
 
Fig. 8. SNC-80 improved motor activity in D2R
-/-
 mice. Administration of the DOP receptor agonist SNC-80 (3 
and 10 mg/Kg; i.p.) produced motor facilitation in D2R
-/-
 mice, being ineffective in D2R
+/+
 mice. Administration 
of the DOP receptor antagonist NTI (1 and 5 mg/Kg; i.p.) was ineffective in both genotypes. Motor activity has 
been assessed as immobility time in the bar test (A, D), number of steps in the drag test (B, E) and time spent on 
the rod in the rotarod test (C, F). All tests were performed before (control session) and 30 min after drug 
administration. Data are means ± SEM of at least 9 determinations per group and are expressed as absolute 
values. 
##
p<0.01 different from D2R
+/+
 mice; *p<0.05; **p<0.01 different from vehicle (ANOVA followed by 
Newman Keuls test for multiple comparisons). 
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2.2 SNC-80 and NTI improved motor activity in D2L
-/-
 mice.  
D2L
-/-
 mice showed similar performances in the bar and rotarod test compared to wild-type 
controls but reduced stepping activity (10.2±0.7 vs 15.3±0.7 steps). SNC-80 was ineffective 
in D2L
+/+
 mice but improved stepping activity at 3 and 10 mg/Kg, in D2L
-/-
 mice (~35% and 
~50%; respectively, Fig. 9A-B). NTI was ineffective in D2L
+/+ 
mice, but facilitated motor 
performance in D2L-/- mice, increasing the number of steps at 1 and 5 mg/Kg (~40% e ~30%, 
respectively;Fig. 9B), and the time on the rod at 5 mg/Kg (~40%Fig. 9F).  
 
 
Fig. 9. SNC-80 and NTI improved motor activity in D2L
-/-
 mice. Administration of the DOP receptor agonist 
SNC-80 (3 and 10 mg/Kg; i.p.) produced motor facilitation in D2L
-/-
 mice, being ineffective in D2L
+/+
 mice. 
Administration of the DOP receptor antagonist NTI (1 and 5 mg/Kg; i.p.) was ineffective in D2L
+/+
 mice, but 
improved motor performance in D2L
-/-
 mice. Motor activity has been assessed as immobility time in the bar test 
(A, D), number of steps in the drag test (B, E) and time spent on the rod in the rotarod test (C, F). All tests were 
performed before (control session) and 30 min after drug administration. Data are means ± SEM of 7 
determinations per group and are expressed as absolute values. 
##
p<0.01 different from D2L
+/+
 mice; *p<0.05; 
**p<0.01 different from vehicle (ANOVA followed by Newman Keuls test for multiple comparisons). 
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Part 3. Targeting RGS-4 as possible approach to restore motor deficits. 
In the last part of the study, we investigated whether selective blockade of RGS-4 was able to 
reduce motor impairments in parkinsonian mice and rats. For this purpose, we used three 
models: neuroleptic-induced parkinsonism in mice, unilaterally 6-OHDA-lesioned mice, and 
unilaterally 6-OHDA-lesioned rats. Moreover, we evaluated if RGS4 inhibition could 
synergize with the DOP receptor agonist SNC-80 in restoring motor deficits in these models. 
In order to achieve selective inhibition of RGS4 we used a selective small molecule inhibitor, 
CCG-203769
220,243
. For hemilesioned animals, the data presented are referred to the forepaw 
contralateral to the lesion side. For rats, due to the heterogeneity between the motor 
performances of the animals, data are expressed as percentages of the basal session. 
 
3.1 CCG-203769 in C57BL/6J naïve mice. 
We first tested the effect of CCG-203769 on motor function of naïve mice. CCG-203769 (1 
and 10 mg/Kg) did not affect motor performance in the bar (Fig. 10A), drag (Fig. 10B) and 
rotarod test (Fig. 10C) over a 90 min observation period. 
 
 
Fig. 10. CCG-203769 was ineffective in C57BL/6J naïve mice. CCG-203769 (1 and 10 mg/Kg, i.p.) did not 
affect motor performance in bar (A), drag (B) and rotarod test (C). All tests were performed before (control 
session) and after (20 and 90 min) CCG-203769 injection. Data are means ± SEM of 6 determinations per group 
and are expressed as absolute values. No significant differences were observed (ANOVA followed by the 
Newman Keuls test for multiple comparison). 
 
3.2 CCG-203769 reversed neuroleptic-induced parkinsonism. 
Here, we investigated the ability of CCG-203769 to reverse motor impairment induced by 
administration of the D2/D3 receptor antagonist raclopride (Part 1).  
Raclopride (1 mg/Kg, i.p.) caused elevation of immobility time and reduction of the number 
of steps and time on rod (Fig. 11A-C), lasting up to 120 min after administration. CCG-
203769 (0.01-10 mg/Kg, i.p.), administered 30 min after raclopride, promptly reversed motor 
impairment in the bar and drag test. The effect was significant at 0.1 mg/Kg, which causes 
full reversal of akinesia in the bar test (Fig. 11A), and partial reversal of akinesia/bradykinesia 
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in the drag test (~50% at 20 min after injection) (Fig. 11B). Higher doses (1 and 10 mg/Kg) 
were fully effective in both tests (Fig. 11A and B). Different from the bar and drag test, at any 
doses, CCG-203796 was able to attenuate impairment of rotarod performance (Fig. 11C). 
 
 
Fig. 11. Motor inhibition induced by pretreatment with the D2/D3 receptor antagonist raclopride (RAC) (1 
mg/Kg, i.p.) was reversed by CCG-203769 (CCG). The effects of CCG-703769 (0.01-10 mg/Kg, i.p.) on the 
immobility time in the bar test (A), the number of steps in the drag test (B) and the time on rod in the rotarod test 
(C) were evaluated. All tests were performed before (pretreatment, control session), 30 min after raclopride 
injection, then 20 and 90 min after SNC-80 or saline (SAL) administration. Data are means ± SEM of at least 6 
determinations per group and are expressed as absolute values. *P<0.05, **p<0.01, different from control 
session; 
#
p<0.05; 
##
p<0.01, different from raclopride (ANOVA followed by the Newman Keuls test for multiple 
comparison). 
 
3.3 CCG-203769 improved stepping activity in 6-OHDA hemilesioned mice. 
Unilateral intrastriatal injection of 6-OHDA caused marked akinesia and bradykinesia, mainly 
affecting the contralateral forepaw, and an overall reduction of motor performance. The time 
spent on the blocks with the contralateral paw (47.7 ± 2.8 s, n= 8) was greater (p<0.01) than 
the time spent with the ipsilateral paw (20.2 ± 6.8 s), and in the drag test the number of steps 
made by the contralateral forepaw (2.0 ± 0.3 steps, n=8) was significantly lower (p<0.001) 
than that made by the ipsilateral one (20.5 ± 1.2). Also, in these mice the rotarod performance 
(658.4 ± 36.4 s, n=26) was significantly impaired by 50%, if compared with that of naïve 
mice (1223.5 ± 122.7 s, taken from Bido et al.,
236
). 
To test the influence of RGS4 inhibition on locomotive behavior after DA denervation, 6-
OHDA-hemilesioned mice were treated with increasing doses of CCG-203769 (1-30 mg/Kg, 
i.p.). CCG-203769 was unable to affect the immobility time in the bar test (Fig 12A). 
Conversely, it enhanced stepping activity at the contralateral forepaw in the drag test, causing 
a 2-fold increase at 10 mg/Kg, and a 3-fold increase at 30 mg/Kg (Fig. 12B). At this dose the 
effect lasted for up to 3 hrs after administration. No significant improvement of rotarod 
performance were observed, although we should note that after administration of saline or 
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CCG-203796 (1 and 10 mg/Kg) performance declined whereas after the highest dose no 
decline was observed (Fig. 12C).  
 
 
Fig. 12. CCG-203769 enhanced stepping activity in 6-OHDA hemilesioned mice. CCG-203769 (10 and 30 
mg/Kg, i.p.) increased the number of steps at the contralateral forepaw (B), but failed in reducing the immobility 
time in the bar test (A) and in improving overall motor performance in the rotarod test (C). Behavioral testing 
was performed before (pretreatment, control session) and after (20, 90, 180 and 360 min) drug injection. Motor 
asymmetry in the bar and drag tests (A, B) was evaluated separately at the ipsilateral (not shown) and 
contralateral paw. Data are expressed as absolute values and are means ± SEM of 5-8 animals per group. 
*p<0.05, **p<0.01 different from control session (ANOVA followed by the Newman Keuls test for multiple 
comparison). 
 
3.4 CCG-203769 improved stepping activity in 6-OHDA hemilesioned rats. 
As described for mice, hemiparkinsonian rats showed hypoactivity, which predominantly 
affected the contralateral (parkinsonian) paw and led to motor asymmetry. Indeed, the time 
spent on the blocks with the contralateral paw (53.8 ± 0.8 s) was greater (p<0.001) than the time 
spent with the ipsilateral paw (38.0 ± 1.5 s). Moreover, the number of steps made by the 
contralateral forepaw (1.8 ± 0.1 steps) was significantly lower (p<0.001) than that made by the 
ipsilateral one (9.1 ± 0.3). Finally, the motor performance on the rotarod of hemiparkinsonian 
rats (724.9 ± 101.2 s; n=59) was reduced compared to that of naïve animals (1044 ± 50 s; taken 
from Marti et al., 2005
145
). 
CCG-203769 (0.3-10 mg/Kg) was ineffective in the bar (Fig. 13A) and rotarod (Fig 13C) tests 
but improved motor performance in the drag test (Fig. 13B). In particular, CCG-203769 was 
ineffective at 0.3 mg/Kg, produced a ~2.5-fold increase in stepping activity at 1 mg/Kg and a 
less than 2-fold increase at higher doses (Fig. 13B). Only the effect of 1 mg/Kg CCG-203769 
was evident, albeit much attenuated, at 90 min after injection.  
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Fig. 13. CCG-203769 improved motor activity in 6-OHDA hemilesioned rats. Effect of CCG-203769 (0.3-10 
mg/Kg, i.p.) in the bar (A), drag (B) and rotarod (C) tests. Data are expressed as percentages of basal motor activity 
in the control session and are mean ± SEM of 7-13 determinations per group.  
*p<0.05, **p<0.01 different from saline (ANOVA followed by the Newman Keuls test for multiple comparison). 
 
3.5 Interaction between CCG-203769 and SNC-80 in PD models. 
One of the main problem related to therapy with DOP receptor agonists, is the development 
of side-effects at high doses, the most threatening of which are convulsions
244-246
. Blockade of 
RGS4 might be a promising strategy to circumvent these issues
220,221,247
, although the 
interaction between RGS4 inhibitors and DOP receptor ligands in PD models has never been 
tested. 
 
3.5.1 SNC-80 restored raclopride-induced motor deficits. 
As expected based on previous data in D2R
-/-
 mice, SNC-80 (0.1-3 mg/Kg, i.p.) restored 
motor activity previously inhibited by raclopride (1 mg/Kg, i.p.). SNC-80 reduced immobility 
time in the bar test (Fig. 14A). A partial reversal of akinesia was observed with 0.1 mg/Kg, 
full reversal being observed at higher doses (1 and 10 mg/Kg). In the drag test, 0.1 mg/Kg 
SNC-80 was found ineffective whereas 1 and 3 mg/Kg SNC-80 fully restored stepping 
activity (Fig. 14B). In the rotarod test, all doses significantly enhanced the time on the rod at 
20 min after drug injection, only the 0.1 mg/Kg dose was effective also 90 min after injection 
(Fig. 14C). 
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Fig. 14. Dose-response curve of SNC-80 after pre-treatment with the D2/D3 receptor antagonist raclopride. 
Raclopride (RAC) (1 mg/Kg, i.p.) produced motor inhibition, which was reversed by administration of SNC-80 
(0.1-3 mg/Kg, i.p). Motor activity was evaluated as immobility time in the bar test (A), number of steps in the 
drag test (B) and time on the rod in the rotarod test (C). All tests were performed before (control session), 30 
min after raclopride injection, then 20 and 90 min after SNC-80 or saline (SAL) administration. Data are mens ± 
SEM of 6-9 determinations per group and are expressed as absolute values. **p<0.01 different from control 
session; 
#
p<0.05, 
##
p<0.01 different from raclopride (ANOVA followed by the Newman Keuls test for multiple 
comparison). 
 
3.5.2 Co-administration of CCG-203769 and SNC-80 synergistically improved motor 
performance after raclopride pretreatment. 
To investigate whether RGS4 inhibition could enhance the antiparkinsonian effect of DOP 
ligands, CCG-203769 was tested along with SNC-80. A combination of sub-threshold doses 
of CCG-203769 (i.e. 0.01 mg/Kg) and sub-threshold doses of SNC-80 (0.01 mg/Kg) was first 
tested. In this set of experiments, each compound alone failed to affect motor performance (as 
expected), whereas the combination caused significant reduction of immobility time and 
improvement of stepping activity (Fig. 15A and B). No synergistic effect, however, was 
observed in the rotarod tests, where performance remained impaired after drug administration 
(Fig. 15C). 
In the attempt to obtain a significant improvement of rotarod performance, we escalated the 
doses of both compounds. In the bar test, CCG-203769 (0.1 mg/Kg) was ineffective and did 
not potentiate the antiakinetic effect of SNC-80 (0.1 mg/Kg) (Fig. 16A). 
In the drag test, each compounds alone increased stepping activity, however their combination 
did not result in a significant additive effect (although full reversal was clearly provided by 
the combination). While each compound alone was ineffective in the rotarod test, they 
improved rotarod performance when given in combination. 
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Fig. 15. The co-administration of sub-threshold doses of CCG-203769 and SNC-80 improved motor activity 
after raclopride pre-treatment. CCG-203769 (0.01 mg/Kg, i.p.) and SNC-80 (0.01 mg/Kg, i.p.), ineffective alone, 
were able to restore motor performance in raclopride-pretreated mice in the bar (A) and drag (B), but not in the 
rotarod (C) tests when given together. All tests were performed before (control, pretreatment session), 30 min 
after raclopride (RAC) administration, then 20 and 90 min after drug (CCG; SNC) or saline (SAL) 
administration. Data are means ± SEM of 5-9 determinations per group and are expressed as absolute values. 
*p<0.05, **p<0.01 different from control session; 
#
p<0.05, 
##
p<0.01 different from raclopride (ANOVA 
followed by the Newman Keuls test for multiple comparison). 
 
 
Fig. 16. The co-administration of intermediate doses of CCG-203769 and SNC-80 restored motor performance 
also in the rotarod test. Motor impairment induced by raclopride (RAC) (1 mg/Kg, i.p.) was reversed by co-
administration of CCG-203769 (0.1 mg/Kg, i.p.) and SNC-80 (0.1 mg/Kg, i.p.). Motor activity has been 
evaluated as immobility time in the bar test (A), number of steps in the drag test (B) and time spent on the rod in 
the rotarod test (C). All tests were performed before (control, pretreament session), 30 min after raclopride 
(RAC), then 20 and 90 min after drug (CCG; SNC) or saline (SAL) administration. Data are means ± SEM of 5-
11 determinations per group and are expressed as absolute values. *p<0.05, **p<0.01 different from control 
session; 
##
p<0.01 different from raclopride (ANOVA followed by the Newman Keuls test for multiple 
comparison). 
 
3.5.3 SNC-80 improved motor performance in 6-OHDA hemilesioned mice. 
Previous studies of our group demonstrated that systemic administration of the DOP receptor 
agonist SNC-80 improved motor performance in 6-OHDA hemilesioned rats
248
. Here we 
investigated whether SNC-80 could attenuate motor deficit also in 6-OHDA hemilesioned 
mice. SNC-80 (0.1-3 mg/Kg) reduced the time spent on the blocks (~26% and ~17%, at 20 
and 90 min after injection, respectively) (Fig. 17A), and improved stepping activity (~380% 
and 315%, at 20 and 90 min after injection, respectively) (Fig. 17B) at the contralateral 
43 
forepaw at 0.1 mg/Kg. Maximal reduction of akinesia in the bar test was observed with 3 
mg/Kg SNC-80, whereas maximal increase of stepping activity was observed with 1 mg/Kg 
SNC-80. Conversely, SNC-80 failed to improve rotarod performance (Fig. 17C). 
 
 
Fig. 17. SNC-80 improved motor activity in 6-OHDA hemilesioned mice. Effect of systemic administration of 
the non-peptidic DOP receptor agonist SNC-80 (0.1-3 mg/Kg, i.p.) in the bar (A), drag (B) and rotarod (C) tests. 
Each experiments consisted of three different sessions: a control session followed by other two sessions 
performed at 20 and 90 min after saline or SNC-80 administration. Motor asymmetry was evaluated separately at 
the ipsilateral (not shown) and contralateral paw (A, B). Data are expressed as absolute values and are means ± 
SEM of 6-10 animals per group. *p<0.05, **p<0.01 different from control session (ANOVA followed by the 
Newman Keuls test for multiple comparison). 
 
3.5.4 The co-administration of CCG-203769 and SNC-80 was not more effective than 
each compound alone in promoting stepping activity in 6-OHDA hemilesioned mice. 
To investigate whether CCG-203769 could potentiate the effects of SNC-80 in reducing 
parkinsonian motor deficit in 6-OHDA hemilesioned mice, animals were treated with 
effective doses of the two compounds. In the bar test, CCG-203769 (10 mg/Kg, i.p.) was 
ineffective, whereas SNC-80 (0.1 mg/Kg, i.p.) alone or combined with CCG-703769 reduced 
the immobility time at 20 min (~20%) and 90 min (~25%) (Fig. 18A). In the drag test, CCG-
203769, SNC-80 and their combination caused a similar ~4-fold increase in stepping activity 
at 20 and 90 min (Fig. 18B). No significant effects were observed in the rotarod test (Fig. 
18C), but a mild decrease (~25%) on the rotarod performance was observed at 360 min after 
injection, probably due to the weariness of the animals at the end of the experimental session. 
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Fig. 18. Effects of the co-administration of CCG-203769 and SNC-80 in 6-OHDA hemilesioned mice. The effects 
of SNC-80 (0.1 mg/Kg, i.p.), CCG-703769 (10 mg/Kg, i.p.) and their co-application on the immobility time in the 
bar test (A), the number of steps in the drag test (B) and the time on rod in the rotarod test (C) were evaluated. 
Motor asymmetry was evaluated separately at the ipsilateral (not shown) and contralateral paw (A, B). Data are 
means ± SEM of 8 determinations per group and are expressed as absolute values. *<0.05, **p<0.01 different from 
saline (ANOVA followed by the Newman Keuls test for multiple comparison). 
 
3.5.5 SNC-80 improved motor performance in 6-OHDA hemilesioned rats. 
Different from that observed for CCG-203769, SNC-80 produced a remarkable antiparkinsonian 
effect in all three tests (Fig. 19). SNC-80 dose-dependently reduced the immobility time, 
increased stepping activity and rotarod performance, being ineffective at 0.1 mg/Kg and 
maximally effective at 3 mg/Kg (-60%, +120%, and +60%; respectively; Fig. 19). 
We finally tested two different combinations of CCG-203769 and SNC-80. In the first set of 
experiment (Fig. 20), we challenged together sub-threshold (ineffective) doses of both 
compounds (CCG-203769 0.3 mg/Kg and SNC-80 0.1 mg/Kg). This combination caused a 
synergistic, >2-fold increase in stepping activity at the contralateral paw at 20 min, and a ~50% 
increase at 90 min (Fig. 20B). Likewise, the combination was ineffective in modulating motor 
activity in the other tests (Fig 20A and C). 
In the second set of experiments (Fig 21), we evaluated the combination of a full dose of CCG-
203769 (1 mg/Kg) with a sub-threshold dose of SNC-80 (0.1 mg/Kg). CCG-203769 alone 
improved stepping at 1 mg/Kg but this effect was not enhanced by SNC-80. 
 
 
Fig. 19. SNC-80 improved motor activity in 6-OHDA hemilesioned rats. Effect of SNC-80 (0.1-3 mg/Kg, i.p.) in 
the bar (A), drag (B) and rotarod (C) tests. Data are expressed as percentages of basal motor activity in the control 
session and are mean ± SEM of 9-13 determinations per group. *p<0.05, **p<0.01 different from vehicle (ANOVA 
followed by the Newman Keuls test for multiple comparison). 
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Fig. 20. The effects of SNC-80 (0.1 mg/Kg, i.p.), CCG-703769 (0.3 mg/Kg, i.p.) and their co-application on the 
immobility time in the bar test (A), the number of steps in the drag test (B) and the time spent on the rod in the 
rotarod test (C) were evaluated. Data are means ± SEM of 8-12 determinations per group and were calculated as 
percentages of control session. *p<0.05, **p<0.01 different from SNC-80 ; 
#
 p<0.05, 
## 
p<0.01 different from CCG-
203769 (ANOVA followed by the Newman Keuls test for multiple comparison). 
 
 
Fig. 21. The effects of SNC-80 (0.1 mg/Kg, i.p.), CCG-703769 (1 mg/Kg, i.p.) and their co-application on the 
immobility time in the bar test (A), the number of steps in the drag test (B) and the time spent on the rod in the 
rotarod test (C) were evaluated. Data are means ± SEM of 8-12 determinations per group and were calculated as 
percentages of basal activity. **p<0.01 different from SNC-80 (ANOVA followed by the Newman Keuls test for 
multiple comparison). 
 
 
 
 
 
 
 
 
 
 
 
46 
Discussion 
Part 1 
Previous studies suggested that the post-synaptic D2L isoform is responsible of the motor 
inhibition induced by neuroleptics
240
, indeed in D2L
-/-
 mice, the cataleptic response to these 
drugs was reduced
234,249
. Our results show that the motor inhibitory effect of raclopride is lost 
in D2R
-/-
 and D2L
-/-
 mice, confirming that raclopride acts at post-synaptic D2 receptors. 
NOP receptors induce a dual modulation of motor activity in naïve mice as shown after 
central injection of the peptide NOP receptor antagonist UFP-101 or systemic administration 
of the nonpeptide NOP receptor antagonists J-113397, Trap-101, GF-4 and Compound 
24
147,149,250,251
. 
The motor facilitatory responses elicited by NOP receptor antagonists disappeared after 
raclopride-pretreatment or genetic deletion of D2L receptors. NOP receptor antagonists are 
able to increase striatal DA release by inhibiting N/OFQ tone on nigral DA neurons
146,252
. 
Based on this evidence, it is feasible that NOP receptor antagonists promote motor activity 
through an increase of endogenous DA release and activation of D2 post-synaptic receptors. 
Unexpectedly, we obtain the same loss of motor facilitation administering low doses of 
N/OFQ in presence of raclopride, or in D2L
-/-
 and D2R
-/-
 mice. These findings suggest that 
low doses of N/OFQ or NOP receptor antagonists share the same pathways. Indeed, while 
NOP receptor antagonists probably block a direct N/OFQ inhibitory tone on nigral DA 
neurons, low N/OFQ doses might elevate DA release through other mechanisms involving 
other endogenous opioids
253
. 
Motor inhibition induced by high doses of NOP receptor antagonists is attenuated after pre-
treatment with the D2/D3 antagonist amisulpride, lost in D2R
-/-
 mice and preserved in D2L
-/-
 
mice; these data suggest that the NOP antagonist-mediated motor impairment is under D2 
autoreceptors control. Although difficult to explain, we could suggest that profound blockade 
of the constitutive N/OFQ inhibitory tone on nigral DA neurons would cause a massive 
release of DA, which in turn activate an inhibitory feedback loop via D2S autoreceptors. The 
resulting reduction of DA release at synaptic terminals suppresses post-synaptic D1 and D2 
receptor mediated transmission
234,254,255
. Indeed, treatment with amisulpride, which acts at 
D2S autoreceptors, unmasks the motor facilitatory effects mediated by D2L post-synaptic 
receptors, in 2010 Viaro and colleagues showed that motor inhibition induced by high doses 
of the NOP receptor antagonist J-113397 was reversed into facilitation in presence of 
amisulpride
152
. Another hypothesis is based on the theorized existence of post-synaptic D2S 
receptors, which may oppose their inhibitory action to D1 receptors
234
. 
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The different D2 receptor sensitivity of high doses of J-113397 relative to those of exogenous 
N/OFQ is undeniable, indeed for the antagonist, motor inhibition is lost in D2R
-/-
 mice, while 
for the agonist, motor suppression is preserved in both genotypes. This evidence indicates that 
the inhibitory effects of J-113397 are mediated by D2 autoreceptors, whereas the N/OFQ-
induced hypolocomotion derives from a direct inhibitory effect of N/OFQ on DA release in 
nigro-striatal
146
 and mesoaccumbal
153,256,257
 DA neurons. The markedly compromised basal 
motor activity of D2R
-/-
 mice
233
 makes it difficult the assessment of any further inhibition, but 
it is noteworthy that in D2R
-/-
 mice, high doses of N/OFQ attenuate motor performance in the 
bar and drag test, suggesting that the inhibitory effect of N/OFQ could partially be mediated 
by D2R, indeed, since NOP and D2S receptors are both expressed by nigral DA neurons, a 
possible NOP-D2S interaction could occur. 
Part 2 
In the second part of this work, we extended the investigation on the contribution of DA D2 
receptor transmission to the motor actions exerted by DOP receptor ligands. 
SNC-80 did not alter motor performance in D2R
+/+
 and D2L
+/+
mice. This finding contrasts 
with previous reports
55,258
, showing that SNC-80 was able to enhance motor activity in wild-
type mice, using the open field test. 
This discrepancy might be due to the different mice strain and the different motor tests used in 
our study; indeed the effects on spontaneous motor activity, reported in those studies, could 
actually reflect changes in affective states rather than motor function. For example, the well-
known anxiolytic effect of DOP receptor agonists might explain the enhanced exploratory 
activity in the open field. 
Surprisingly, the genetic ablation of the D2 receptor (D2R
-/-
) or its long post-synaptic isoform 
(D2L
-/-
), disclosed a facilitatory effect of SNC-80 on motor activity. This indicates a possible 
negative D2/DOP receptor interaction, which could take place at membrane, cellular or 
network level. 
D2R
-/-
 mice show a dramatic motor impairment, with profound akinesia and bradykinesia in 
the bar and drag tests and an overall reduction in rotarod performance . It has been shown that 
the density of the DOP receptor or the levels of its mRNA decrease in the CPu, NAcc, globus 
pallidus (GP) and ventral pallidum of rats chronically treated with haloperidol or 
fluphenazine-N-mustard, an irreversible D2 antagonist
55,259-261
. Moreover, DOP receptor 
mRNA down-regulation was associated with a marked increase in the expression of striatal 
preproekephalin mRNA
261,262
. Such a change has also been described in the striatum of each 
of the three different lines of D2R
-/-
 mice generated to date
233,263,264
, and has been explained as 
being due to the removal of tonic inhibition exerted by the D2 receptors on the expression of 
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enkephalins. These data suggest that the increase in ENKs levels in D2R
-/-
 mice may be an 
adaptive response to compensate for the deficient DAergic transmission, and despite down-
regulation of DOP receptors, DOP receptor activation represents a mechanism to rescue 
motor function. 
To confirm such compensatory role of DOP receptors, SNC-80 increased locomotor activity 
and motor coordination in hemiparkinsonian rats
248
 and in MPTP-treated non-human 
primates
52
, while the antagonist NTI diminished abnormal movements classically described in 
the 6-OHDA model
57
. 
Unexpectedly, the DOP antagonist NTI was able to promote motor activity in D2L
-/-
 mice to 
the same extent of SNC-80, being effective also in the rotarod test, where SNC-80 has no 
effect. Although paradoxical, this finding is consistent with the hyperkinetic phenotype of 
DOP
-/-
 mice
127,265,266
. Moreover, it has been recently shown that the DOP agonist UFP-512 at 
low dose increased locomotor coordination in a hemiparkinsonian rat model, and had opposite 
effects at a high dose
56
. This would indicate that different DOP receptors may mediate both 
motor stimulation and inhibition. Indeed, in the striatum DOP receptor are predominantly 
expressed by cholinergic interneurons
128-130
, but a small proportion of DOP receptors is also 
present on GABAergic interneurons and on pre-synaptic glutamatergic terminals
131
. 
Consequently blocking DOP receptor signaling may have multiple potential consequences on 
striatal functions. For example, we could hypothesize that the improvement in striatal 
function may derive from the blockade of DOP receptors located on GABAergic interneurons 
and/or glutamatergic terminals. 
Part 3 
In the third part of this study, we report that the RGS4 inhibitor, CCG-203769, reverses 
neuroleptic-induced parkinsonism and improved stepping activity in 6-OHDA hemilesioned 
mice and rats.  
Recent papers suggest a potential role for RGS proteins in long-term adaptation processes 
observed in response to pharmacological treatment
195,196
 or occurring during the development 
of neurodegenerative diseases
193
. RGS4 is highly expressed in the striatum
165
 and there is 
evidence linking changes in RGS4 function to a variety of neurological diseases, including 
PD, Huntington’s disease, and addiction201,267-269. 
Thus, it is no surprise that CCG-203769 specifically improved stepping activity in the drag 
test, a test very closely releated to striatal sensory-motor functions
270
. Our results also confirm 
genetic data
185
, showing that RGS4
-/-
 mice have fewer behavioral deficits following DA 
depletion with 6-OHDA than wild-type mice. It has been shown that the expression of several 
RGS proteins changes rapidly with alterations in DAergic signaling
201,268,271,272
, for example, 
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loss of RGS4 in striatal cholinergic interneurons
267
 may contribute to the improved phenotype 
of RGS4
-/-
 mice following DA depletion, since RGS4 is expressed in these cell types
203
. 
Interestingly, RGS4 also co-localizes with D2 receptors
202
, which are expressed by striato-
pallidal neurons. Also in this case, blockade of RGS4 might amplify the positive effect of 
residual endogenous DA or the therapeutic effects of a D2 agonist. Although down-regulation 
of RGS4 may be an adaptive change that already takes place in response to DA 
depletion
268,273
, our data indicate that further inhibition, by means of the small molecule 
inhibitor CCG-203769, is beneficial.  
Opioid receptors signaling is negatively modulated by RGS proteins
199,274
. The selectivity of 
RGS proteins in this role lies in their ability to interact with opioid receptors and their cognate 
G proteins. This selectivity is determined by various factors, including tissue specific 
expression and precise interaction with the intracellular domains of receptor proteins, G 
protein subunits, and effectors as well as other pathway-specific components
170
. In this work, 
we unveil, for the first time, the synergistic interaction between a RGS4 inhibitor and a DOP 
receptor agonist in functional and neurodegeneration PD models. Although this synergism 
was overall mild, it nevertheless proves the functional role of endogenous RGS4 in vivo, and 
the therapeutic potential of pharmacological targeting.  
Previous in vitro studies showed that RGS4 reverted DOP receptor agonist-induced inhibition 
of cAMP synthesis in membranes prepared from NG108 cells
182
. Furthermore, 
overexpression of RGS4 in HEK293 cells attenuate DAMGO- and DPDPE-induced inhibition 
of adenylyl cyclase
179,208
. Although revealing a negative regulatory role of RGS4 on opioid 
receptor signaling, these data did not confirm a physiological role for endogenous RGS4 in 
nontransfected systems. In 2009, Wang and coworkers demonstrated the existence of a 
selective interaction between endogenous RGS4 protein and DOP receptor signaling in native 
system, providing evidence for a receptor-specific effect of RGS4
210
. In 2011, the same group 
demonstrated that the DOP receptor agonist DPDPE caused a marked reduction in levels of 
RGS4 protein and that this down-regulation was accompanied by a loss of opioid receptors
275
. 
There are also in vivo data showing that DOP receptor agonists are able to modulate RGS 
proteins expression; indeed SNC-80, as a nonmonoamine-based putative antidepressant, has 
been shown to reduce RGS4 levels in PFC and to have greater antidepressant-like efficacy in 
RGS4 knockout mice
247
. Based on these different lines of evidence, we could reasonably 
suppose that the activation of DOP receptor and the inhibition of RGS4 positively cooperate 
in modulating motor functions when DA transmission is compromised.  
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Concluding remarks 
 
The results obtained can be summarized as follows: 
 
i. N/OFQ is a powerful modulator of DA release and transmission, as demonstrated by using 
a combined pharmacological and genetic approach. The motor facilitation induced by low 
doses of N/OFQ is mediated by D2L post-synaptic receptors, whereas motor inhibition 
induced by high doses of N/OFQ occurs also in absence of D2 receptors and is likely due 
to direct inhibition of mesencephalic DA neurons. NOP receptor blockade with low doses 
of NOP receptor antagonists promotes DA release and has facilitatory effects on motor 
activity, which are likely mediated by post-synaptic D2L receptors activation. On the other 
hand, increased doses of NOP receptor antagonists have suppressing effects on 
locomotion, probably mediated by D2S autoreceptors. These data corroborate the view that 
modulating N/OFQ system may represent an alternative way to control locomotion and 
other DA-dependent functions in vivo. 
ii. The absence of post-synaptic D2 receptors discloses a motor promoting action of DOP 
receptor ligands, suggesting the existence of a D2/DOP receptor interaction, which might 
occur both at the membrane and network level. As D2R
-/-
 mice have been considered a 
model of PD, the presented data indicate that the antiparkinsonian action of DOP receptor 
agonists is DA-independent, which may represent a therapeutic advantage over classical 
DAergic drugs. 
iii. The inhibition of RGS4 protein, by means of the small molecule inhibitor, CCG-203769, 
reverts motor impairment in different parkinsonism models. Moreover, the co-application 
of CCG-203769 with the DOP receptor agonist SNC-80 synergizes in attenuating motor 
deficits. These data suggest that molecules that stabilize or otherwise reduce the actions of 
RGS4, with suitable characteristics for clinical use, might have the potential of being PD 
symptomatic therapeutics, alone or in combination with other drugs in the therapy of PD. 
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